Ligand-targeted molecules and methods thereof

ABSTRACT

The present invention relates to ligand-targeted molecules and ligand drug conjugates (LDCs) comprising a ligand connected to a functional group, which is connected to a linker, with in turn is bonded to a drug. The LDCs of the present invention also comprise platinum coordination complex wherein the platinum is connected to the linker through monocarboxylato and O—*Pt coordinate bonds. The present invention also relates to methods for preparing these ligand drug conjugates. The present invention further relates to methods for the treatment of tumours using the ligand drug conjugates of the present invention.

RELATED APPLICATIONS

This application is a Divisional Application of U.S. application Ser.No. 14/370,524 filed Jul. 3, 2014, which is a 35 U.S.C. § 371 NationalPhase Entry Application of International Application No.PCT/US2013/020130 filed Jan. 3, 2013, which designates the U.S., andwhich claims benefit under one or more of 35 U.S.C. § 119(a)-119(d) ofIndian Patent Application No. 18/DEL/2012 filed Jan. 3, 2012, thecontent of which is incorporated herein by reference in its entirety.

TECHNICAL FIELD

The present invention relates to ligand-targeted molecules and liganddrug conjugates. The present invention also relates to methods ofpreparing these ligand-targeted molecules and ligand drug conjugates, aswell as methods of using these ligand drug conjugates for the treatmentof tumours.

BACKGROUND

Despite recent improvements in cancer therapy due to the introduction ofnovel therapeutics, the incidence of cancer has been on the rise.Traditional chemotherapy is still one of the pillars for the treatmentof cancer. Chemotherapy is often based on the use of drugs that aretoxic to cancer cells. Several general classes of chemotherapeutic drugshave been developed. One such class of genotoxic drugs that have beenshown to damage cellular DNA by producing crosslinks therein arecisplatin [cis-diamminedichloroplatinum(II)] and carboplatin[diammine(1,1-cyclobutanedicarboxylato)-platinum(II)] (Eur J Cancer1998; 34:1535-42; Chem Rev. 1999; 2467-98). Cisplatin is one of the mostcommonly used chemotherapeutic agents, and is a first line therapy formost malignancies. Cisplatin and other Pt(II) analogs, such ascarboplatin and oxaliplatin, are currently used in the treatment ofselected, diverse neoplasms of epithelial and mesenchymal origin.

However, traditional chemotherapeutic agents are not tumour specific;their selectivity largely relies on the premise that rapidlyproliferating cells are more prone to the cytotoxic effect of thesedrugs. Therefore, increased toxicities against normal tissuescharacterized by an enhanced proliferation rate represent a majordrawback of this approach. As consequence of this low efficacy andunspecific toxicity, chemotherapeutics are often given at suboptimaldoses. For example, Cisplatin and related Pt (II) agents arecharacterised by nephrotoxicity, neurotoxcity and myelosupression. Thus,the unmet medical need is for innovative strategies that focus toxicityto tumor cells while sparing healthy tissues. The development ofantibody-drug conjugates (ADCs) by empowering antibodies or atargeting-ligand with a cytotoxic drug directed against tumor-associatedantigens represents a promising therapeutic strategy for site-specificdrug delivery.

The antibody-drug conjugate (ADCs) concept is a promising strategy todeliver a cytotoxic drug selectively to a target. Such conjugatesrepresent a broadly applicable approach to enhance the antitumoractivity of antibodies, and improve the tumor-to-normal tissueselectivity of chemotherapy (Cancer J 2008; 14:154-169). A significantnumber of ADCs are currently in clinical development, and recentlyBrentuximab vedotin (SGN-35) has been approved by the FDA (CCR Focus,Clin Can Res 2011:17). Although immuno-conjugates of doxorubicin (CancerRes. 1992; 15; 5693-700), cisplatin (J Pharm Sci. 1997; 86:1478-83) andtaxanes (Cancer Res 2001; 61, 694-699) has been tried before, developingantibody-targeted chemotherapeutics has been a challenge. The majorproblem associated were loss of structural integrity of antibodies anddrug potency. Significant progress in these areas has been made, withcareful optimization of several parameters, including antibodyspecificity, drug potency, linker technology, and the stoichiometry andplacement of conjugated drugs (Curr Opin Chem Biol. 2010; 14:529-37).

Site-specific delivery of platinum compounds to tumor cells has beenattempted previously. This was achieved by directly complexing platinumto PEG and delivering the drug in the untargeted form or asligand-targeted conjugate to tumor associated antigens. In one report,attempt was made to conjugate carboplatin with PEG (Polym Adv Technol.2000; 11:635-41). In other examples of prior art, folate-targetedPEGylated carboplatin analogs (Bioconj Chem. 2003; 14:563-74) as well aspeptide-targeted carboplatin were tested on tumor cells in vitro(Bioconj Chem. 2004; 4:814-23). The complexes were ineffective forpractical usage in terms of cytotoxicity, antigen binding activity andin vivo stability. The limitations associated to previous versions ofPt-antibody conjugates could be attributed to the use of antibodies ofmurine origin, the choice of the cell surface receptor, method ofsynthesis resulting in the potential binding of Pt to the antibodydisulfides, or inability of the Pt to aquate due to formation of stablelinkages resulting in inefficient release kinetics.

SUMMARY

This invention relates to the generation and usage of novel platinum(II) co-ordination compounds linked to a targeting ligand where theplatinum is co-ordinated to a leaving group via an unique O—Pt and a═O→Pt coordinate bond. The invention also provides complexes for thesite-specific or disease-specific delivery of chemotherapeutic agentsfor anti-cancer therapy. The present invention contemplates the use ofdifferent Pt (II) compounds and other cytotoxins, different targetingmoieties in the format of ligand-targeted therapeutics. In any form, theconjugates may contain one or more Pt (II) therapeutic agents, and oneor more targeting ligands.

The present invention is directed to ligand-targeted moleculescomprising a hydrocarbon- or PEG-containing linker connected to aplatinum moiety through a monocarboxylato and/or coordinate bond. Theseligand-targeted molecules comprise a suitable functional moietyconnected to a linker, which is connected to a dicarbonyl moeity, whichin turn in connected to a platinum chemotheraputic agent. The presentinvention also provides ligand-targeted molecules wherein the linkercomprises a Pt (II) coordination complex which is turn is connected to acytotoxic agent or drug.

The present invention further discloses methods of preparingligand-targeted molecules of the present invention comprising: a) areacting amino acid, amino acid conjugate or peptide withmaleimide-PEG-HOOC to obtain an intermediate; b) coupling theintermediate with a carboxylic acid or its derivative to obtain acarboxylate adduct; c) reacting the carboxylate adduct with a platinum(II) chemotherapeutic agent to form the ligand-targeted molecule. Thepresent invention is also directed to methods of preparing ligand drugconjugates of the present invention comprising conjugating theligand-targeted molecule of the present invention with a ligand. Thepresent invention is also directed to methods of treating tumours usingthe molecules and conjugates of the invention.

Still another aspect of the invention is directed to pharmaceuticalcompositions comprising a conjugate described herein and apharmaceutically acceptable carrier.

Yet another aspect of the invention is directed to a method of treatingcancer or metastasis. The method includes selecting a subject in need oftreatment for cancer or metastasis and administering to the subject aneffective amount of any of the compounds, conjugates or compositionsdescribed herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A shows a general structure of a ligand-drug conjugate whereplatinum act as a linker by forming dicarboxylato linkages. It isflanked by a non-polar spacer and to the drug by a PEG spacer.

FIG. 1B shows a general structure of a ligand-drug conjugate whereplatinum acts as a linker by forming dicarboxylato linkages. It isflanked on either side by a PEG spacer.

FIG. 1C shows a general structure of a ligand-drug conjugate whereplatinum acts as a linker by forming a monocarboxylato and O→Ptcoordinate bond. It is flanked on either side by a PEG spacer.

FIGS. 1D-1F show general structures of some exemplary ligand-drugconjugates.

FIG. 2 shows a general structure of a ligand-drug conjugate containingtwo linker-drug complex.

FIG. 3 shows a general structure of a cisplatin/oxaliplatin basedantibody-drug conjugates (ADC) where linker lysine is conjugated to PEGwith α-amine.

FIG. 4 shows a general structure of a cisplatin/oxaliplatin based ADChere linker lysine is conjugated to PEG with ε-amine.

FIG. 5 is a schematic representation of Ligand-Drug Conjugate (LDC)comprising a linker coupled with multiple cytotoxic drugs.

FIG. 6 shows a general structure of a oxaliplatin based LDC where linkeris conjugated to multiple platinum drugs.

FIG. 7 shows the structure of an epithelial growth factor receptor(EGFR)-targeted monoclonal antibody Oxaliplatin-linked monolysinatedlinker based ADC.

FIG. 8 shows the structure of an EGFR-targeted monoclonal antibodyOxaliplatin linked monolysinated linker based ADC. The succinate Pt(II)complex linked via the α-NH₂ group of lysine.

FIG. 9 shows the structure of an EGFR-targeted monoclonal antibodyOxaliplatin linked tri-lysinated linker based antibody-drug conjugate(ADC).

FIG. 10 shows the structure of an antibody-targeted Pt(II) coordinationcomplex conjugated to the cytotoxic drug 27-hydroxybullatacin via anester-linkage.

FIG. 11 shows the structure of an antibody-targeted Pt(II) coordinationcomplex conjugated to the cytotoxic drug meayamycin via anester-linkage.

FIGS. 12A and 12B are synthesis scheme for the synthesis oftri-lysinated Pt(II) analogs conjugated to the anti-EGFR monoclonalantibody. Reagents and Conditions: a) HoBT, EDCI, Dry DCM, DIPEA, 12 h,rt; b) H2, Pd, Ethylacetate, 6 h, rt; c) HoBT, EDCI, Dry DCM,Na-Cbz-Ne-Boc-L-Lysine, d) H2, Pd, Ethylacetate, 6 h, rt; e) HoBT, EDCI,HOOC-PEG-Mal, Dry DCM, DIPEA, 12 h, rt; f) TFA, Dry DCM, 3 h, 0oC; g)succinic anhydride, pyridine, Dry DCM, 12 h, rt; h) Cis-diamminedihydroplatinum(II), DMF, H2O, 24 h, rt; i) Antibody-SH (EGFRmAb-SH).

FIGS. 13A and 13B are schematic representation of the scheme for thesynthesis of a ADC using Pt(II) coordination linker-drug complex.

FIGS. 14A-14C are schematic representation of the scheme for thesynthesis of an antibody conjugated to the cytotoxic drug27-hydroxybullatacin using Pt(II) coordination linker (steps 1-3).

FIGS. 15A-15C are schematic representation of the scheme for thesynthesis of an antibody conjugated to the cytotoxic drug meayamycinusing Pt(II) coordination linker (steps 1-3).

FIGS. 16A-16C are schematic representations of antibody-drug conjugatesusing a non-cleavable, platinum comprising linker. In FIGS. 16A and 16B,the free amine of lysine can be coupled to a spacer with a chelatingunit with platinum. In FIG. 16C, two thiol group of the reduced antibodycan bind to platinum with stable (non-cleavable) bond.

FIG. 17 is a schematic representation of an antibody-drug conjugateusing a Pt(II) complex in the linker.

FIGS. 18-20 are schematic representations of ligand drug conjugatesusing a platinum complex comprising linker and antibody as the targetingmoiety.

DETAILED DESCRIPTION

The present invention is directed to ligand drug conjugates and theirapplication as ligand-targeted therapeutics. The ligand-targetedmolecules (LTM) of the present invention are conjugated to potentcytotoxic drugs to form ligand drug conjugates (LDC) which can beselectively delivered to a site of action of interest in an active form,and then cleaved to release the active drug.

The present invention provides a cytotoxic ligand-drug conjugate havingthe structure of Formula 1:

Formula 1

The formula above represents use of platinum as a drug per se or as acleavable linker linking another cytotoxic agent/drug to the ligand.

In some embodiments, the drug is a Pt(II) agent conjugated to the linkerby forming a Pt-coordination complex.

Another embodiment of the present invention also provides a novelligand-drug conjugate wherein the linker includes the platinumcoordination complex, and a drug, e.g., a cytotoxic drug is conjugatedto the linker via the platinum. The platinum-coordination complex isbonded with cytotoxic drugs either through dicarbonyl linkages to thelinker or through monocarbonyl linkages and O→Pt coordinate bond.Without limitations, the LDCs described herein can release the drug fromthe complex upon internalization into the cells. In these compounds, theplatinum complex can act as a leaving group not as the drug. It servesas a linker that can be readily cleaved, thus providing an LDC thatcleaves to release the cytotoxic agent/drug that is attached to the Ptmoiety.

In another embodiment of the novel LDC, the linker coordination complexcould have other metals such as Fe, Si to conjugate the cytotoxic agent.

In one aspect, the present disclosure provides a ligand-drug conjugatecomprising a targeting moiety and a drug conjugated to each other via alinker, wherein the drug is a platinum compound. In some embodiments ofthis aspect, the ligand-drug conjugate is of formula A-B—C, wherein A isa ligand (e.g., a targeting moiety); B is a linker; and C is platinumcompound.

In another aspect, the present disclosure provides a ligand-drugconjugate comprising a targeting moiety and a drug conjugated to eachother via a linker, wherein the linker comprises a platinumcompound/complex. In some embodiments of this aspect, the ligand-drugconjugate is of formula A-B—C—B′-D, wherein A is a ligand (e.g., atargeting moiety); B and B′ are independently a linker; C is acoordination metal complex (e.g., a platinum complex); and D istherapeutic agent or drug. In embodiments of this aspect, the drug canbe a second platinum compound or another cytotoxic agent/drug.

The disclosure also provides a conjugates of formula F-B—C, wherein F isa functional group, B is a linker, and C is a platinum compound.

The disclosure also provides a conjugate of formula F-B—C—B′-D, whereinF-B—C—B′-D, wherein F is functional group; B and B′ are independently alinker; C is a coordination metal complex (e.g., a platinum complex);and D is drug. The functional group can be used to link the linker Bwith a targeting moiety or ligand.

In some embodiments, the platinum compound is linked to the linker via adicarbonyl monomer present in the linker.

In some embodiments, the platinum compound is dissociably linked to thelinker via at least one coordination bond. Without wishing to be boundby theory, the coordination bond is more liable and thus releases theplatinum compound more easily relative to when the platinum compound islinked to the linker without the use of a coordination bond. In someembodiments, linking of the platinum compound to the linker furthercomprises a carboxylato bond. Accordingly, in some embodiments, theplatinum compound is linked to the linker through a coordination bondand a carboxylato bond.

In some embodiments, the coordination bond is between platinum atom ofthe platinum compound and an oxygen of the dicarbonyl monomer of thelinker. Preferably the coordination bond is between platinum and acarbonyl oxygen. In some embodiments, the coordination bond is betweenplatinum atom of the platinum compound and an amide oxygen of thelinker. In some embodiments, the coordination bond is between platinumatom of the platinum compound and an ester carbonyl oxygen linker.

In some embodiments, at least one (e.g., one, two, three, four, five,six, seven, eight, nine, ten or more) platinum compounds are linked tothe linker. Without limitations, any platinum compound can be used inthe conjugates described herein. In some embodiments, the platinumcompound is a platinum(II) or platinum (IV) compound. In someembodiments, the platinum (II) compound is selected from the groupconsisting of cisplatin, oxaliplatin, carboplatin, paraplatin,sartraplatin, and combinations thereof.

In some embodiments, the platinum(II) compound is selected from thegroup consisting of Pt(NH₃)₂, Pt(NH₃)(2-methylpyridine), and

wherein p is 0, 1, 2, or 3. In one embodiment, the platinum (II)compound is Pt(NH₃)₂.

In some embodiments, the platinum (II) compound comprises at least twonitrogen atoms, where said nitrogen atoms are directly linked toplatinum. In a further embodiment, the two nitrogen atoms are linked toeach other via an optionally substituted linker, e.g. acyclic or cycliclinker. A cyclic linker means a linking moiety that comprises at leastone ring structure. Cyclic linkers can be aryl, heteroaryl, cyclyl orheterocyclyl.

In some embodiments, the at least one nitrogen that is linked toplatinum is a ring atom of a heteroaryl or a heterocyclyl. In oneembodiment, heteroaryl is optionally substituted pyridine, e.g.,2-methylpyridine.

In some embodiments, the platinum compound is

wherein p is 2.

Without limitations any drug (e.g., therapeutic agent) can be conjugatedin the targeting ligands drug conjugates described herein. As usedherein, the term “therapeutic agent” refers to a substance used in thediagnosis, treatment, or prevention of a disease. Any therapeutic agentknown to those of ordinary skill in the art to be of benefit in thediagnosis, treatment or prevention of a disease is contemplated as atherapeutic agent in the context of the present invention. Therapeuticagents include pharmaceutically active compounds, hormones, growthfactors, enzymes, DNA, plasmid DNA, RNA, siRNA, antisenseoligonucleotides, aptamers, ribozymes, viruses, proteins, lipids,pro-inflammatory molecules, antibodies, antibiotics, anti-inflammatoryagents, anti-sense nucleotides and transforming nucleic acids orcombinations thereof. Any of the therapeutic agents can be combined tothe extent such combination is biologically compatible.

Exemplary therapeutic agents include, but are not limited to, thosefound in Harrison's Principles of Internal Medicine, 13^(th) Edition,Eds. T. R. Harrison et al. McGraw-Hill N.Y., NY; Physicians DeskReference, 50^(th) Edition, 1997, Oradell New Jersey, Medical EconomicsCo.; Pharmacological Basis of Therapeutics, 8^(th) Edition, Goodman andGilman, 1990; United States Pharmacopeia, The National Formulary, USPXII NF XVII, 1990; current edition of Goodman and Gilman's ThePharmacological Basis of Therapeutics; and current edition of The MerckIndex, the complete contents of all of which are incorporated herein byreference.

Examples of therapeutic agents which can be used, include but are notlimited to, narcotic analgesic drugs; salts of gold; corticosteroids;hormones; antimalarial drugs; indole derivatives; pharmaceuticals forarthritis treatment; antibiotics, including Tetracyclines, Penicillin,Streptomycin and Aureomycin; antihelmintic and canine distemper drugs,applied to domestic animals and large cattle, such, as, for example,phenothiazine; drugs based on sulfur, such, as sulfioxazole; antitumordrugs; pharmaceuticals supervising addictions, such as agentscontrolling alcohol addiction and agents controlling tobacco addiction.;antagonists of drug addiction, such, as methadone; weightcontrollingdrugs; thyroid gland controlling drugs; analgesics; drugs controllingfertilization or contraception hormones; amphetamines; antihypertensivedrugs; antiinflammatories agents; antitussives; sedatives; neuromuscularrelaxants; antiepileptic drugs; antidepressants; antidisrhythmic drugs;vasodilating drugs; antihypertensive diuretics; antidiabetic agents;anticoagulants; antituberculous agents; antipsychotic agents; hormonesand peptides. It is understood that above list is not full and simplyrepresents the wide diversification of therapeutic agents that may beincluded in the compositions. In some embodiments, therapeutic agent isMitoxantrone, protein (e.g. VEGF) or plasmid DNA.

In some embodiments, the therapeutic agent, e.g., the drug is ananti-cancer agent. As used herein, the term “anti-cancer agent” isrefers to any compound (including its analogs, derivatives, prodrugs andpharmaceutically salts) or composition which can be used to treatcancer. Anti-cancer compounds for use in the present invention include,but are not limited to, inhibitors of topoisomerase I and II, alkylatingagents, microtubule inhibitors (e.g., taxol), and angiogenesisinhibitors. Exemplary anti-cancer compounds include, but are not limitedto, paclitaxel (taxol); docetaxel; gemicitabine; Aldesleukin;Alemtuzumab; alitretinoin; allopurinol; altretamine; amifostine;anastrozole; arsenic trioxide; Asparaginase; BCG Live; bexarotenecapsules; bexarotene gel; bleomycin; busulfan intravenous; busulfanoral;calusterone; capecitabine; carboplatin; carmustine; carmustine withPolifeprosan Implant; celecoxib; chlorambucil; cisplatin; cladribine;cyclophosphamide; cytarabine; cytarabine liposomal; dacarbazine;dactinomycin; actinomycin D; Darbepoetin alfa; daunorubicin liposomal;daunorubicin, daunomycin; Denileukin diftitox, dexrazoxane; docetaxel;doxorubicin; doxorubicin liposomal; Dromostanolone propionate; Elliott'sB Solution; epirubicin; Epoetin alfa estramustine; etoposide phosphate;etoposide (VP-16); exemestane; Filgrastim; floxuridine (intraarterial);fludarabine; fluorouracil (5-FU); fulvestrant; gemtuzumab ozogamicin;goserelin acetate; hydroxyurea; Ibritumomab Tiuxetan; idarubicin;ifosfamide; imatinib mesylate; Interferon alfa-2a; Interferon alfa-2b;irinotecan; letrozole; leucovorin; levamisole; lomustine (CCNU);mechlorethamine (nitrogenmustard); megestrol acetate; melphalan (L-PAM);mercaptopurine (6-MP); mesna; methotrexate; methoxsalen; mitomycin C;mitotane; mitoxantrone; nandrolone phenpropionate; Nofetumomab; LOddC;Oprelvekin; oxaliplatin; pamidronate; pegademase; Pegaspargase;Pegfilgrastim; pentostatin; pipobroman; plicamycin; mithramycin;porfimer sodium; procarbazine; quinacrine; Rasburicase; Rituximab;Sargramostim; streptozocin; talbuvidine (LDT); talc; tamoxifen;temozolomide; teniposide (VM-26); testolactone; thioguanine (6-TG);thiotepa; topotecan; toremifene; Tositumomab; Trastuzumab; tretinoin(ATRA); Uracil Mustard; valrubicin; valtorcitabine (monoval LDC);vinblastine; vinorelbine; zoledronate; and any mixtures thereof. In someembodiments, the anti-cancer agent is a paclitaxel-carbohydrateconjugate, e.g., a paclitaxel-glucose conjugate, as described in U.S.Pat. No. 6,218,367, content of which is herein incorporated by referencein its entirety.

In some embodiments, the drug is selected from the group of drugs shownin Table 1.

TABLE 1 Some exemplary drugs for conjugating with the targeting-ligand.Drug Class Mechanism Source IC50 Remarks Maytansinoid AnsamycinMicrotuble Ethiopian nM to (DM1 and disruptors Shrub pM DM4) CC-1065Binds to minor Bacteria nM to groove of DNA pM and alkylation AdozelesinSynthetic Synthetic 0.02 nM Poor (DC1) analogue of solubility CC-1065 inaqueous system DC4 Water soluble Synthetic analogue of DC1Calicheamicins Antibiotics Binds to minor Picomolar Poor groove, strandpharmaceutic breaks index Dolastatins Cyclic Microtuble Sea hareSystemic pentapeptides disruptors Dolabella cytotoxicity auriculariaAuristatins E Synthetic Microtuble Synthetic nM to and F analogues ofdisruptors pM dolastatins Meamycin Analogue of Binds to Synthetic;picomolar Active FR901464 splicing factor derived from against 3bPseudomonas MDR cells too Doxorubucin Antibiotic Natural High nMPaclitaxel Terpenoids Microtubule Pacific yew stabilizer tree DocetaxelMicrotubule stabilizer Laulimalide Macrolide Microtubule sponge Low nMIntrinsically (Paclitaxel- stabilizer Cacospongia unstable like)mycofijiensis Epothilones A Macrolide Microtubule myxobacterium Activeand B (Paclitaxel- stabilizer Sorangium against like) cellulosum MDRcells too Discodermolide polyhydroxylated Microtubule marinealkatetraene stabilizer sponge lactones Discodermia (Paclitaxel-dissoluta like) Eleutherobin Terpenoids Microtubule soft coral(Paclitaxel- stabilizer Eleutherobia like) sp. Peloruside A MacrolideMicrotubule marine Low nM (Paclitaxel- stabilizer sponge, like) Mycalehentscheli cyclophosphamide, Nitrogen Alkylating Synthetic chlorambucil,mustards agent uramustine, ifosfamide, melphalan, and bendamustineCarmustine, Nitrosoureas Alkylating Synthetic lomustine, agentssemustine Busulfan Alkyl Alkylating Synthetic sulfonates agents ThiotepaAlkylating Synthetic agents Dacarbazine Alkylating Synthetic agentsMethotrexate Antimetabolites Folate Synthetic antagonist 6-Antimetabolites Purine Synthetic mercaptopurine, antagonist6-thioguanine, pentostatin, fludarabine 5-fluorouracil, AntimetabolitesPyrimidine Synthetic cytarabine, antagonist leukovorin DactinomycinAntibiotics Natural Bleomycin Antibiotics Natural DaunorubicinAntibiotics Natural Mitomycin Antibiotics Natural Idarubicin AntibioticsNatural Plicamycin Antibiotics Natural Vincristine Plant alkaloidsMitotic inhibitors Vinblastine Plant alkaloids Mitotic inhibitorsVinorelbine Plant alkaloids Mitotic inhibitors Etoposide Plant alkaloidsinhibition of American High nM topoisomerase 1 Mayapple Teniposide Plantalkaloids inhibition of Low nM topoisomerase II Asparaginase EnzymeMaitotoxin activates Ca2+ Gambierdiscus permeable, non- toxicusselective cation channels Irinotecan Semi-synthetic inhibition of(CPT-11) alkaloid topoisomerase 1 Fumagillin angiogenesis Aspergillusinhibitor fumigatus Fumagalone Fumarranol O- (Chloroacetylcarbamoyl)-Fumagillol (AGM-1470, TNP-470) 27- Acetogenins A. glabra Low pMhydroxybullatacin

In some embodiments, the drug is epothilone, auristatins, maytansine,dolastatins, laulimalide, meayamycin, 27-hydroxybullatacin,calicheamicin, or a derivative of any of the foregoing.

As used herein, the term “linker” means an organic moiety that connectstwo parts of a compound. Linkers typically comprise a direct bond or anatom such as oxygen or sulfur, a unit such as NH, C(O), C(O)NH, SO, SO₂,SO₂NH or a chain of atoms, such as substituted or unsubstituted alkyl,substituted or unsubstituted alkenyl, substituted or unsubstitutedalkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl,heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl,heterocyclylalkenyl, heterocyclylalkynyl, aryl, heteroaryl,heterocyclyl, cycloalkyl, cycloalkenyl, alkylarylalkyl,alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl,alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl,alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl,alkylheteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkyl,alkenylheteroarylalkenyl, alkenylheteroarylalkynylalkynylheteroarylalkyl, alkynylheteroarylalkenyl,alkynylheteroarylalkynyl, alkylheterocyclytalkyl,alkylheterocyclylalkenyl, alkylhererocyclylalkynyl,alkenylheteracyclylalkyl, alkenylheterocyclylalkenyl,alkenylheterocyclylalkynyl, alkynylheterocyclylalkyl,alkynylheterocyclylalkenyl, alkynylheterocyclylalkynyl, alkylaryl,alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl,alkynylhereroaryl, where one or more methylenes can be interrupted orterminated by O, S, S(O), SO₂, NH, C(O). The terms linker and spacer areused interchangeably herein.

In some embodiments, the linker comprises at least one (e.g., one, two,three, four, five, six, seven, eight, nine, ten or more) monomer forlinking the platinum compound with the linker.

In some embodiments, the monomer for linking the platinum compound withthe linker is a dicarbonyl compound. In some embodiments, the dicarbonylmonomer is

wherein q is 0, 1, 2, 3, 4, or 5. In some embodiments, q is 2.

In some embodiments, the dicarbonyl monomer is aspartic acid, whereinthe aspartic acid is linked with the linker via the amino group of theaspartic acid, i.e., the dicarbonyl compound is

In some embodiments, the dicarbonyl monomer is —C(O)—R—CO₂H, wherein Ris a bond, an optionally substituted C₁-C₆ alkylene, where the alkylenecan comprise one or more double or triple bonds. In some embodiments, Ris —CH₂—, —CH₂CH₂—, —CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂CH₂—, or—CH₂CH₂CH₂CH₂CH₂CH₂—.

In some embodiments, the dicarbonyl monomer is a succinate monomer,wherein the succinic acid is linked to the linker via one of thecarboxylic groups, i.e., the dicarbonyl monomer is

In some embodiments, for linking the platinum compound with the linker,the linker comprises a monomer of formula

wherein s is 0, 1, 2, 3, 4, or 5. These monomers are also referred to asamino-thiol monomers herein.

In some embodiments, for linking the platinum compound with the linker,the linker comprises a monomer of formula

wherein t is 0, 1, 2, 3, 4, or 5. These monomers are also referred to asamino-thiol-carbonyl monomers herein.

In some embodiments, for linking the platinum compound with the linker,the linker comprises a monomer of formula

wherein r is 0, 1, 2, 3, 4, or 5.

In some embodiments, for linking the platinum compound with the linker,the linker comprises a monomer of formula

wherein R^(L) is an optionally substituted linker, e.g. acyclic orcyclic linker. These monomers are also referred to as diamino monomersherein. A cyclic linker means a linking moiety that comprises at leastone ring structure. Cyclic linkers can be aryl, heteroaryl, cyclyl orheterocyclyl. In some further embodiments of this, the monomer offormula

In still some further embodiments of this, the monomer of formula

In some embodiments, the linker comprises at least one cleavable linkinggroup. A cleavable linking group is one which is sufficiently stableoutside the cell, but which upon entry into a target cell is cleaved torelease the two parts the linker is holding together. In a preferredembodiment, the cleavable linking group is cleaved at least 10 times ormore, preferably at least 100 times faster in the target cell or under afirst reference condition (which can, e.g., be selected to mimic orrepresent intracellular conditions) than in the blood or serum of asubject, or under a second reference condition (which can, e.g., beselected to mimic or represent conditions found in the blood or serum).

Cleavable linking groups are susceptible to cleavage agents, e.g., pH,redox potential or the presence of degradative molecules. Generally,cleavage agents are more prevalent or found at higher levels oractivities inside cells than in serum or blood. Examples of suchdegradative agents include: redox agents which are selected forparticular substrates or which have no substrate specificity, including,e.g., oxidative or reductive enzymes or reductive agents such asmercaptans, present in cells, that can degrade a redox cleavable linkinggroup by reduction; esterases; amidases; endosomes or agents that cancreate an acidic environment, e.g., those that result in a pH of five orlower; enzymes that can hydrolyze or degrade an acid cleavable linkinggroup by acting as a general acid, peptidases (which can be substratespecific) and proteases, and phosphatases.

A linker can include a cleavable linking group that is cleavable by aparticular enzyme. The type of cleavable linking group incorporated intoa linker can depend on the cell to be targeted. In some embodiments,cleavable linking group is cleaved at least 1.25, 1.5, 1.75, 2, 3, 4, 5,10, 25, 50, or 100 times faster in the cell (or under in vitroconditions selected to mimic intracellular conditions) as compared toblood or serum (or under in vitro conditions selected to mimicextracellular conditions). In some embodiments, the cleavable linkinggroup is cleaved by less than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%,10%, 5%, or 1% is in the blood (or in vitro conditions selected to mimicextracellular conditions) as compared to in the cell (or under in vitroconditions selected to mimic intracellular conditions).

Exemplary cleavable linking groups include, but are not limited to,redox cleavable linking groups (e.g., —S—S— and —C(R)₂—S—S—, wherein Ris H or C₁-C₆ alkyl and at least one R is C₁-C₆ alkyl such as CH₃ orCH₂CH₃); phosphate-based cleavable linking groups (e.g., —O—P(O)(OR)—O—,—O—P(S)(OR)—O—, —O—P(S)(SR)—O—, —S—P(O)(OR)—O—, —O—P(O)(OR)—S—,—S—P(O)(OR)—S—, —O—P(S)(OR)—S—, —S—P(S)(OR)—O—, —O—P(O)(R)—O—,—O—P(S)(R)—O—, —S—P(O)(R)—O—, —S—P(S)(R)—O—, —S—P(O)(R)—S—,—O—P(S)(R)—S—, —O—P(O)(OH)—O—, —O—P(S)(OH)—O—, —O—P(S)(SH)—O—,—S—P(O)(OH)—O—, —O—P(O)(OH)—S—, —S—P(O)(OH)—S—, —O—P(S)(OH)—S—,—S—P(S)(OH)—O—, —O—P(O)(H)—O—, —O—P(S)(H)—O—, —S—P(O)(H)—O—,—S—P(S)(H)—O—, —S—P(O)(H)—S—, and —O—P(S)(H)—S—, wherein R is optionallysubstituted linear or branched C₁-C₁₀ alkyl); acid cleavable linkinggroups (e.g., hydrazones, esters, and esters of amino acids, —C═NN— and—OC(O)—); ester-based cleavable linking groups (e.g., —C(O)O—);peptide-based cleavable linking groups, (e.g., linking groups that arecleaved by enzymes such as peptidases and proteases in cells, e.g.,—NHCHR^(A)C(O)NHCHR^(B)C(O)—, where R^(A) and R^(B) are the R groups ofthe two adjacent amino acids). A peptide based cleavable linking groupcomprises two or more amino acids. In some embodiments, thepeptide-based cleavage linkage comprises the amino acid sequence that isthe substrate for a peptidase or a protease found in cells.

In some embodiments, an acid cleavable linking group is cleaveable in anacidic environment with. a pH. of about 6.5 or lower (e.g., about 6.-,5.5, 5.0, or lower), or by agents such as enzymes that acan act as ageneral acid.

In some embodiments, the linker comprises is an acid labile group, e.g.,hydrazide or acetylphenoxy-butaonic. In some embodiments, the linkercomprises an enzyme labile group e.g.,maleimidecaproyl-valyl-citrullinyl-p-aminobenzylcarbamate.

In some embodiments, the linker comprises non-cleavable group e.g., athio-ether linkage.

In some embodiments, the linker comprises a peptide, e.g., a dipeptideor a tripeptide.

In some embodiments, the linker comprises a disulfide linkage.

In some embodiments the linker comprises a self-immolative disulfidelinkage.

In some embodiments, the linker is a bond.

It is to be understood that the linker can be modified to comprisefunctional groups for linking with the targeting moiety. Thus, in someembodiments, the linker comprises a functional group at one end(terminus) of the linker for linking the linker with the targetingmoiety. When the linker comprises a functional group, the linker can beconsider as F-B, wherein F is the functional group and B is linkerwithout the functional group. Thus, the disclosure also providestargeting moiety (or ligand) drug conjugates described herein whereinthe targeting moiety is absent, e.g., the bond linking the linker withthe targeting moiety is replaced with a hydrogen.

As used herein, the functional group comprises at least two reactivemoieties, one for connecting to the targeting moiety or ligand and theother for connecting to the linker. In some embodiments the functionalgroup is thiol reactive, amine reactive or azide reactive. An example ofa functional group is a group containing a thiol-reacting moiety and anamine-reacting moiety. Other examples of functional groups includealdehydes or ketones forming hydrazide linkages, in some embodiments,the functional group is maleimide group.

In some embodiments, the linker is a hydrocarbon, polyethylene; glycol(PEG), an amino acid, a peptide, or a combination thereof. Thehydrocarbon or PEG can be substituted or unsubstituted.

In some embodiments, the linker is a polyethylene glycol of a molecularweight of about 200 Da to about 50 kDa.

In some embodiments, the linker is comprises an optionally modified PEGand at least one amino acid, (e.g., one, two, three, four, five, six,seven, eight, nine, ten or more amino acids).

In some embodiments, the linker is comprises an optionally modified PEGand two amino acids, e.g., a dipeptide.

In some embodiments, the linker is comprises an optionally modified PEGand three amino acids, e.g., a tripeptide.

In some embodiments, the linker comprises at least one lysine residue.

In some embodiments, the linker is

wherein each R¹ is independently H, alkyl (e.g., C₁-C₆ alkyl), or aryl;X¹ is NH, O, or S; X² is a polyethylene glycol; and X³ is an amino acidor a peptide comprising from two to ten amino acids. Withoutlimitations, X³ can comprise natural and/or unnatural amino acids.

In some embodiments, X¹ is NH.

In some embodiments, X² is —(CH₂CH₂O)_(a)—, wherein a is from 3 to 100.

In some embodiments, X³ is an amino acid, a dipeptide, or a tripeptide.In some embodiments, X³ is -Lys-Z—, -Lys-Lys-Z—, -Lys-Lys-Lys-Z—,-Lys-Ala-Lys-Z—, wherein Z is succinic acid, aspartic acid, serine,threonine, a dicarbonyl monomer described herein, an amino-thiol monomerdescribed herein, an amino-thiol-carbonyl monomer described herein, or adiamino monomer described herein.

In some embodiments, the linker is

wherein each R¹ is independently H, alkyl C₁-C₆ alkyl), or aryl; R² is amono or dicarboxylic acid, a dicarbonyl monomer described herein, anamino-thiol monomer described herein, an amino-thiol-carbonyl monomerdescribed herein, or a diamino monomer described herein; R³ is H, alkyl,or aryl; n is 0, 1, 2, 3, 4, or 5; X⁴ is polyethylene glycol; p is 1, 2,or 3; and m is 2-100.

In some embodiments, R¹ is H.

In some embodiments, R² is succinic acid, aspartic acid, serine, orthreonine.

In some embodiments, R² is

—C(O)—R—CO₂H, wherein R is a bond, an optionally substituted C₁-C₆alkylene, where the alkylene can comprise one or more double or triplebonds;

wherein s is 0, 1, 2, 3, 4, or 5;

wherein t is 0, 1, 2, 3, 4, or 5;

wherein r is 0, 1, 2, 3, 4, or 5; or

wherein R^(L) is an optionally substituted linker, e.g. acyclic orcyclic linker. A cyclic linker means a linking moiety that comprises atleast one ring structure. Cyclic hikers can be aryl, heteroaryl, cyclylor heterocyclyl. In some further embodiments of this the monomer offormula

In still some further embodiments of this the monomer of formula

is

In some embodiments, R² is

In some embodiments, R³ is H or methyl.

In some embodiments, n is 2.

In some embodiments, p is 1.

In some embodiments, the linker is

wherein variables are as defined above.

In some embodiments, the l inker is

wherein p is 1, 2, or 3; and m is 1-100.

In the above shown structures, the moieties

can be replaced by a maleimide

group to form a linker having a functional group at one end, e.g.,conjugates of formula F-B, F-B—C, or F-B—C—B′-D, wherein F is functionalgroup, B is a linker, C is platinum compound, and D is a drug.

In some embodiments, the linker comprises a co-ordination metal complex,e.g., the linker is —B—C—B′—, wherein are B and B′ are independently alinker and C is coordination metal complex. The coordination metalcomplex can either form part of the linker backbone or be present as asidechain to the linker backbone. Exemplary co-ordination metalcomplexes include complexes of Pt, Fe, Si and the like. For example theco-ordination complex can comprise tetraamminecopper(II) sulphate, iron,or silicon. Thus, as used herein, the linker can also include a Pt(II)coordination complex capable of being covalently bonded to a drug orcytotoxic agent. The drug can be attached to the platinum coordinationcomplex via an amide, ester, amine, ether, hydrazide, disulfides orimine linkages.

In some embodiments, the co-ordination metal complex is a platinumcomplex. In some embodiments, the complex comprises at least onecoordination bond.

In some embodiments, the platinum complex is

wherein b is 0, 1, 2, 3, 4, or 5 and R⁵ is a cyclic or acyclic linkerjoining the two amino groups to rest of the linker, in some embodiments,b is 1.

In some embodiments, R⁵ is

In some embodiments, R⁵ is a cyclic linker selected from aryl,heteroaryl, cyclyl or heterocyclyl. In some embodiments, the platinumcomplex is

In one embodiment, the platinum complex is

In one embodiment, the platinum complex is

In some embodiments, the platinum complex is

wherein c is 0, 1, 2, 3, 4, or 5 and R⁶ is acyclic or acyclic linkerjoining the two amino groups to rest of the linker. In some embodiments,c is 1.

In some embodiments, R^(6 is)

In some embodiments, R⁶ is a cyclic linker selected from aryl,heteroaryl, cyclyl or heterocyclyl. In some embodiments, the platinumcomplex is

In one embodiment, the platinum complex is

In some embodiments, the platinum complex is

wherein d is 0, 1, 2, 3, 4, or 5. In some embodiments, d is 1.

In some embodiments, the platinum complex is

wherein e is 0, 1, 2, 3, 4, or 5. In some embodiments, e is 1.

In some embodiments, the platinum complex is

wherein f is 0, 1, 2, 3, 4, or 5 and R⁷ is a cyclic or acyclic linkerjoining the two amino groups to rest of the linker.

In one embodiment, f is 1.

In some embodiments, R⁷ is

In some embodiments, R⁷ is a cyclic linker selected from aryl,heteroaryl, cyclyl or heterocyclyl.

In some embodiments, the platinum complex is

In some embodiments, the platinum complex is

wherein g is 0, 1, 2, 3, 4, or 5 and R⁸ is a cyclic or acyclic linkerjoining the two amino groups to rest of the linker. In one embodiment gis 1

In some embodiments, R⁸ is

In some embodiments, R⁸ is a cyclic linker selected from aryl,heteroaryl, cyclyl or heterocyclyl.

In some embodiments, the platinum complex is

wherein R⁹ is a cyclic or acyclic linker joining the two amino groups torest of the linker. In some embodiments, R⁹ is

In some embodiments, R⁹is a cyclic linker selected from aryl,heteroaryl, cyclyl or heterocyclyl. In one embodiments, the platinumcomplex is

As used herein the term “targeting moiety” or “targeting ligand” refersto any molecule that provides an enhanced affinity for a selectedtarget, e.g., a cell, cell type, tissue, organ, region of the body, or acompartment, e.g., a cellular, tissue or organ compartment. Thetargeting moiety or ligand can comprise a wide variety of entities. Suchligands can include naturally occurring molecules, or recombinant orsynthetic molecules.

Exemplary targeting ligands include, but are not limited to, antibodies,fragments of antibodies, antigens, folates, receptor ligands,carbohydrates, aptamers, integrin receptor ligands, chemokine receptorligands, transferrin, biotin, serotonin receptor ligands, PSMA,endothelin, GCPII, somatostatin, LDL and HDL ligands. Additionalexemplary ligands include, but are not limited to, polylysine (PLL),poly L-aspartic acid, poly L-glutamic acid, styrene-maleic acidanhydride copolymer, poly(L-lactide-co-glycolied) copolymer, divinylether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamidecopolymer (HMPA), polyethylene glycol (PEG, e.g., PEG-2K, PEG-5K,PEG-10K, PEG-12K, PEG-15K, PEG-20K, PEG-40K), MPEG, [MPEG]₂, polyvinylalcohol (PVA), polyurethane, poly(2-ethylacryllic acid),N-isopropylacrylamide polymers, polyphosphazine, polyethylenimine,cationic groups, spermine, spermidine, polyamine,pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine,arginine, amidine, protamine, cationic lipid, cationic porphyrin,quaternary salt of a polyamine, thyrotropin, melanotropin, lectin,glycoprotein, surfactant protein A, mucin, glycosylated polyaminoacids,transferrin, bisphosphonate, polyglutamate, polyaspartate, aptamer,asialofetuin, hyaluronan, procollagen, immunoglobtilins (e.g.,antibodies), insulin, transferrin, albumin, sugar-albumin conjugates,intercalating agents (e.g., acridines), cross-linkers (e.g. psoralen,mitomycin C), porphyrins (e.g., TPPC4, texaphyrin, Sapphyrin),polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine),artificial endonucleases (e.g., EDTA), lipophilic molecules (e.g.,steroids, bile acids, cholesterol, cholic acid, adamantane acetic acid,1-pyrene butyric acid, dihydrotestosterone,1,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol,borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid,myristic acid, O3-(olcoyl)lithocholic acid, O3-(olcoyl)cholenic acid,dimethoxytrityl, or phenoxazine), peptides (e.g., an alpha helicalpeptide, amphipathic peptide, RGD peptide, cell permeation peptide,endosomolytic/fusogenic peptide), alkylating agents, phosphate, amino,mercapto, polyamino, alkyl, substituted alkyl, radiolabeled markers,enzymes, haptens (e.g. biotin), transport/absorption facilitators (e.g.,naproxen, aspirin, vitamin E, folic acid), synthetic ribonucleases(e.g., imidazole, bisimidazole, histamine, imidazole clusters,acridine-imidazole conjugates, Eu3+ complexes of tetraazamacrocycles),dinitrophenyl, HRP, AP, antibodies, hormones and hormone receptors,lectins, carbohydrates, multivalent carbohydrates, vitamins (e.g.,vitamin A, vitamin E, vitamin K, vitamin B, e.g., folic acid, B12,riboflavin, biotin and pyridoxal), vitamin cofactors,lipopolysaccharide, an activator of p38 MAP kinase, an activator ofNF-κB, taxon, vincristine, vinblastine, cytochalasin, nocodazole,japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine,myoservin, tumor necrosis factor alpha (TNFalpha), interleukin-1 beta,gamma interferon, natural or recombinant low density lipoprotein (LDL),natural or recombinant high-density lipoprotein (HDL), and acell-permeation agent (e.g., a.helical cell-permeation agent).

Peptide and peptidomimetic ligands include those having naturallyoccurring or modified peptides, e.g., D or L peptides; α, β, γ peptides;N-methyl peptides; azapeptides; peptides having one or more amide, i.e.,peptide, linkages replaced with one or more urea, thiourea, carbamate,sulfonyl urea linkages; or cyclic peptides. A peptidomimetic (alsoreferred to herein as an oligopeptidomimetic) is a molecule capable offolding into a defined three-dimensional structure similar to a naturalpeptide. The peptide or peptidomimetic ligand can be about 5-50 aminoacids long, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 aminoacids long.

Carbohydrate based targeting ligands include, but are not limited to,D-galactose, multivalent galactose, N-acetyl-D-galactose (GalNAc),multivalent GalNAc, e.g. GalNAc2 and GalNAc3; D-mannose, multivalentmannose, multivalent lactose, N-acetyl-galactosamine,N-acetyl-gulucosamine, multivalent fucose, glycosylated polyaminoacidsand lectins. The term multivalent indicates that more than onemonosaccharide unit is present. Such monosaccharide subunits can belinked to each other through glycosidic linkages or linked to a scaffoldmolecule.

A number of folate and folate, analogs amenable to the present inventionas ligands are described in U.S. Pat. Nos. 2,816,110; 5,552,545;6,335,434 and 7,128,893, contents of all of which are hereinincorporated in their entireties by reference.

In some embodiments, the targeting ligand binds a protein, receptor, ormarker expressed on the surface of a cancer cell.

In some embodiments, the targeting ligand binds EGFR.

In some embodiments, the targeting ligand is a polyclonal or monoclonalantibody or a fragment thereof retaining epitope binding activity or anantibody-based binding moiety.

In some embodiments, the targeting ligand is a polyclonal or monoclonalantibody, antibody fragments, a peptide, or a molecule that is capableof binding protein receptors expressed on the surface of cancer cells.

As used herein, the term “antibody-based binding moiety” or “antibody”can include immunoglobulin molecules and immunologically activedeterminants of immunoglobulin molecules, e.g., molecules that containan antigen binding site which specifically binds to the fusion protein.The term “antibody-based binding moiety” is intended to include wholeantibodies, e.g., of any isotype (IgG, IgA, IgM, IgE, etc), and includesfragments thereof which are also specifically bind with the fusionprotein or a fragment thereof. Antibodies can be fragmented usingconventional techniques. Thus, the term includes segments ofproteolytically-cleaved or recombinantly-prepared portions of anantibody molecule that are capable of selectively reacting with acertain protein. Non-limiting examples of such proteolytic and/orrecombinant fragments include Fab, F(ab′)2, Fab′, Fv, dAbs and singlechain antibodies (scFv) containing a VL and VH domain joined by apeptide linker. The scFv's can be covalently or non-covalently linked toform antibodies having two or more binding sites. Thus, “antibody-basedbinding moiety” includes polyclonal, monoclonal, or other purifiedpreparations of antibodies and recombinant antibodies. The term“antibody-based binding moiety” is further intended to include humanizedantibodies, bispecific antibodies, and chimeric molecules having atleast one antigen binding determinant derived from an antibody molecule.

In some embodiments, the targeting ligand is an antibody selected fromthe group consisting of C242 antibody (CanAg), Rituximab, Trastuzumab(Her2), Cetuximab, Bevacizumab (VEGF), Panitumumab, Alemtuzumab,Ofatumumab, Gemtuzumab (CD33), Inotuzumab (CD22), Lorvotuzumab (CD56),Brentuximab (CD30), Glembatumumab (GPNMB), epitope bind fragmentsthereof and any combinations thereof.

In some embodiments, the ligand drug conjugate is an antibody-drugconjugate (ADC) wherein the ligand is an antibody having specificity fora tumor-associated antigen (TAA) and the drug is a Pt(II)chemotherapeutic agent. The linker is cleavable inside the cell uponinternalization. Treatment with the ADC leads to inhibition of tumorgrowth. The invention also relates to groups useful for stabilizingchemotherapeutic agents and markers. Stabilizing groups, such as, forexample, PEG, limit clearance and metabolism of the chemotherapeuticagent or marker by enzymes that may be present in blood or non-targettissue. Stabilizing groups may serve to block degradation of thechemotherapeutic agent or marker and may also provide other physicalcharacteristics of the agent or marker, for example, increasing thesolubility of the ligand drug conjugate or decreasing the aggregationproperties of the ligand drug conjugate. The stabilizing group may alsoimprove the stability of the chemotherapeutic agent or marker duringstorage in either a formulated or non-formulated form.

An example of the LDC where the drug is linked via Pt coordinationcomplex is shown in FIGS. 1A-1C.

In one embodiment of the present invention, the functional group is amaleimide group which is bonded with the ligand through a thioetherlinkage and is bonded to the linker via the nitrogen atom of themaleimide group. This embodiment is shown in Formula 2:

wherein:

-   (CHR₁)n-C(═O)—X—P represents the linker, X is N or O, P is a    PEG-containing peptide of natural or unnatural amino acids (Y),    wherein PEG may be linear or branched PEG (n=2-100). One end of the    linker contains a functional group capable of bonding with thiols or    amines, while the other end is a reactive carboxylic acid or amine    capable of forming a covalent linkage with the drug.-   D represents the drug that is coupled to the linker through ester,    amide, disulfide, hydrazide thioether linkage.-   Y can be a single amino acid, di- or tri-peptide of lysine or other    natural or unnatural amino acids, which could be connected with a    chelating group (R2) for platinum as shown in Compound 1.

In another embodiment, R2 is an entity with dicarboxylate groups such asaspartic acid or any other dicarboxylic acid (Compound 2).

In yet another embodiment, R2 as depicted in compound 1 could also be anentity with a monocarbonyl group, such as an amide group and succinicacid, or any combinations thereof, as shown in Compound 3.

In a further embodiment, the platinum (II) drug can be coupled to thedicarboxylate group through two oxygen atoms as shown in Compound 4.

Further, the ligand-targeted molecule is complexed to platinum by thesuccinate through monocarboxylato and O→pt coordinate bond. The Pt(II)-agent in the conjugate is covalently attached to a bifunctionallysine linker and the number of bifunctional lysines is p (p=1-3), asshown below in Compound 5.

In another embodiment, taking advantage of the significant advances madein antibody engineering and other conjugation technologies, andsynthesizing new platinum-analogs with improved toxicity and releasekinetics (PNAS 2010; 107:12435-12440), it is an object of the presentinvention to generate ligand-targeted conjugates of Pt (H) analogs, suchas antibody-drug conjugates which are chemically linkable to monoclonalantibodies or other targeting ligands, in such a way that the desiredcytotoxicity and in vivo stability is obtained.

In another embodiment the linker-drug conjugate is complexed to theligand through a thioether or other covalent linkage. In anotherembodiment of the present disclosure, the lysine-Pt (II) complex iscapable of attaching 1-3 Pt (II) analogs, resulting in 3-12-foldincrease in drug loading per targeting ligand. The Pt is additionallycomplexed with a diaminocyclohexane or diamine moieties, i.e., activatedforms of oxaliplatin or carboplatin and cisplatin post-aquation.

The present invention further provides the ligand drug conjugates (LDCs)shown in FIG. 2. As shown in FIG. 2, these LDCs comprise at least twolinkers attached to the ligand, each linker being further bonded to adrug or cytotoxic agent.

In some embodiments, a LDC of FIG. 2 is a cisplatin/oxaliplatin basedantibody-drug conjugate (ADC) as shown in FIG. 3, wherein linker lysineis conjugated to PEG with α-amine; m=1-3; and n=2-100.

In some embodiments, a LDC of FIG. 2 is a cisplatin/oxaliplatin basedantibody-drug conjugate (ADC) as shown in FIG. 4, wherein linker lysineis conjugated to PEG with ε-amine; m=1-3; and n=2-100.

The present invention also provides ligand drug conjugates (LDCs) asshown in FIG. 5. These LDCs comprise at least two drugs or cytotoxinsattached to the linker.

Exemplary LDCs of FIG. 5 are shown in FIGS. 6 and 9. FIG. 6 depicts ageneral structure of oxaliplatin based LDC where linker is conjugated toa non-polar spacer and multiple Pt(II) drugs. FIG. 7 shows a specificstructure of a Epithelial Growth Factor Receptor (EGFR)-targetedmonoclonal antibody Oxaliplatin-linked monolysinated linker based ADC.The succinate Pt(11) complex linked to the linker via the ε-NH₂ group oflysine; n=2-100. FIG. 8 shows a specific structure of a EpithelialGrowth Factor Receptor (EGFR)-targeted monoclonal antibody Oxaliplatinlinked monolysinated linker based ADC. The succinate Pt(II) complexlinked to the linker via the α-NH₂ group of lysine; n=2-100. FIG. 9shows a specific structure of a Epithelial Growth Factor Receptor(EGFR)-targeted monoclonal antibody Oxaliplatin linked tri-lysinatedlinker based antibody-drug conjugate (ADC). The succinate Pt(II) complexlinked to the linker via the ϵ-NH² group of lysine; n=2-100.

The present invention also provides ligand-drug conjugates (LDCs) wherethe Pt till is part of the linker and the cytotoxic drug is conjugatedto the co-ordination metal complex. The platinum metal acts as theleaving group to release the drug at the site of action. The followingstructures depict some examples of ligand-drug conjugates of FIGS. 1Aand 1B as discussed in foregoing section.

Accordingly, in some embodiments, the ligand drug conjugate of formula.A-B—C—B′-D is selected from the compounds shown in FIGS. 10 and 11. FIG.10 shows structure of an antibody-targeted Pt(II) coordination complexconjugated to the cytotoxic drug 27-hydroxybullatacin via anester-linkage. The Pt(II) linker complex is flanked on one side by anon-polar and other side by a PEG spacer. FIG. 11 shows structure of anantibody-targeted POT) coordination complex conjugated to the cytotoxicdrug meayamycin via an ester-linkage. The Pt(II) linker complex isflanked on both sides by a PEG spacer,

Yet another aspect of the invention is directed to a method of treatingcancer or metastasis. The method includes administering to a subject inneed thereof an effective amount of any of the conjugates, compounds, orcompositions described herein.

For administration to a subject, the conjugates described herein can beprovided in pharmaceutically acceptable compositions. Thesepharmaceutically acceptable compositions comprise atherapeutically-effective amount of one or more of the conjugatesdescribed herein, formulated together with one or more pharmaceuticallyacceptable carriers (additives) and/or diluents. As described in detailbelow, the pharmaceutical compositions of the present invention can bespecially formulated for administration in solid or liquid form,including those adapted for the following: (1) oral administration, forexample, drenches (aqueous or non-aqueous solutions or suspensions),lozenges, dragees, capsules, pills, tablets (e.g., those targeted forbuccal, sublingual, and systemic absorption), boluses, powders,granules, pastes for application to the tongue; (2) parenteraladministration, for example, by subcutaneous, intramuscular, intravenousor epidural injection as, for example, a sterile solution or suspension,or sustained-release formulation; (3) topical application, for example,as a cream, ointment, or a controlled-release patch or spray applied tothe skin; (4) intravaginally or intrarectally, for example, as apessary, cream or foam; (5) sublingually; (6) ocularly; (7)transdermally; (8) transmucosally; or (9) nasally. Additionally,compounds can be implanted into a patient or injected using a drugdelivery system. See, for example, Urquhart, et. al., Ann. Rev.Pharmacol. Toxicol. 24: 199-236 (1984); Lewis, ed, “Controlled Releaseof Pesticides and Pharmaceuticals” (Plenum Press, New York, 1981); U.S.Pat. No. 3,773,919; and U.S. Pat. No. 35 3,270,960.

As used here, the term “pharmaceutically acceptable” refers to thosecompounds, materials, compositions, and/or dosage forms which are,within the scope of sound medical judgment, suitable for use in contactwith the tissues of human beings and animals without excessive toxicity,irritation, allergic response, or other problem or complication,commensurate with a reasonable benefit/risk ratio.

As used here, the term “pharmaceutically-acceptable carrier” means apharmaceutically-acceptable material, composition or vehicle, such as aliquid or solid filler, diluent, excipient, manufacturing aid (e.g.,lubricant, talc magnesium, calcium or zinc stearate, steric acid), orsolvent encapsulating material, involved in carrying or transporting thesubject compound from one organ, or portion of the body, to anotherorgan, or portion of the body. Each carrier must be “acceptable” in thesense of being compatible with the other ingredients of the formulationand not injurious to the patient. Some examples of materials which canserve as pharmaceutically-acceptable carriers include: (1) sugars, suchas lactose, glucose and sucrose; (2) starches, such as corn starch andpotato starch; (3) cellulose, and its derivatives, such as sodiumcarboxymethyl cellulose, methylcellulose, ethyl cellulose,microcrystalline cellulose and cellulose acetate; (4) powderedtragacanth; (5) malt; (6) gelatin; (7) lubricating agents, such asmagnesium stearate, sodium lauryl sulfate and talc; (8) excipients, suchas cocoa butter and suppository waxes; (9) oils, such as peanut oil,cottonseed oil, safflower oil, sesame oil, olive oil, corn oil andsoybean oil; (10) glycols, such as propylene glycol; (11) polyols, suchas glycerin, sorbitol, mannitol and polyethylene glycol (PEG); (12)esters, such as ethyl oleate and ethyl laurate; (13) agar; (14)buffering agents, such as magnesium hydroxide and aluminum hydroxide;(15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18)Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21)polyesters, polycarbonates and/or polyanhydrides; (22) bulking agents,such as polypeptides and amino acids (23) serum component, such as serumalbumin, HDL and LDL; (22) C₂-C₁₂ alchols, such as ethanol; and (23)other non-toxic compatible substances employed in pharmaceuticalformulations. Wetting agents, coloring agents, release agents, coatingagents, sweetening agents, flavoring agents, perfuming agents,preservative and antioxidants can also be present in the formulation.The terms such as “excipient”, “carrier”, “pharmaceutically acceptablecarrier” or the like are used interchangeably herein.

The phrase “therapeutically-effective amount” as used herein means thatamount of a compound, material, or composition comprising a compound ofthe present invention which is effective for producing some desiredtherapeutic effect in at least a sub-population of cells in an animal ata reasonable benefit/risk ratio applicable to any medical treatment. Forexample, an amount of a compound administered to a subject that issufficient to produce a statistically significant, measurable change inat least one symptom of cancer or metastasis,

Determination of a therapeutically effective amount is well within thecapability of those skilled in the art. Generally, a therapeuticallyeffective amount can vary with the subject's history, age, condition,sex, as well as the severity and type of the medical condition in thesubject, and administration of other pharmaceutically active agents.

As used herein, the term “administer” refers to the placement of acomposition into a subject by a method or route which results in atleast partial localization of the composition at a desired site suchthat desired effect is produced. A compound or composition describedherein can be administered by any appropriate route known in the artincluding, but not limited to, oral or parenteral routes, includingintravelious, intramuscular, subcutaneous, transdermal, airway(aerosol), pulmonary, nasal, rectal, and topical (including buccal andsublingual) administration.

Exemplary modes of administration include, but are not limited to,injection, infusion, instillation, inhalation, or ingestion. “Injection”includes, without limitation, intravenous, intramuscular, intraarterial,intrathecal, intraventricular, intracapsular, intraorbital,intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous,subcuticular, intraarticular, sub capsular, subarachnoid, intraspinal,intracerebro spinal, and intrasternal injection and infusion. Inpreferred embodiments, the compositions are administered by intravenousinfusion or injection.

By “treatment”, “prevention” or “amelioration” of a disease or disorderis meant delaying or preventing the onset of such a disease or disorder,reversing, alleviating, ameliorating, inhibiting, slowing down orstopping the progression, aggravation or deterioration the progressionor severity of a condition associated with such a disease or disorder.In one embodiment, at least one symptom of a disease or disorder isalleviated by at least 5%, at least 10%, at least 20%, at least 30%, atleast 40%, or at least 50%.

As used herein, a “subject” means a human or animal. Usually the animalis a vertebrate such as a primate, rodent, domestic animal or gameanimal. Primates include chimpanzees, cynomologous monkeys, spidermonkeys, and macaques, e.g., Rhesus. Rodents include mice, rats,woodchucks, ferrets, rabbits and hamsters. Domestic and game animalsinclude cows, horses, pigs, deer, bison, buffalo, feline species, e.g.,domestic cat, canine species, e.g., dog, fox, wolf, avian species, e.g.,chicken, emu, ostrich, and fish, e.g., trout, catfish and salmon.Patient or subject includes any subset of the foregoing, e.g., all ofthe above, but excluding one or more groups or species such as humans,primates or rodents. In certain embodiments, the subject is a mammal,e.g., a primate, e.g., a human. The terms, “patient” and “subject” areused interchangeably herein. The terms, “patient” and “subject” are usedinterchangeably herein.

Preferably, the subject is a mammal. The mammal can be a human,non-human primate, mouse, rat, dog, cat, horse, or cow, but are notlimited to these examples. Mammals other than humans can beadvantageously used as subjects that represent animal models ofdisorders associated with inflammation.

In addition, the methods described herein can be used to treatdomesticated animals and/or pets. A subject can be male or female. Asubject can be one who has been previously diagnosed with or identifiedas suffering from or having a disorder a cancer or metastasis, but neednot have already undergone treatment.

The conjugates of the invention are also useful in combination withknown anti-cancer treatments, including radiation. The methods of theinvention are especially useful in combination with anti-cancertreatments that involve administering a second drug that acts in adifferent phase of the cell cycle.

Some Selected Definitions

For convenience, certain terms employed herein, in the specification,examples and appended claims are collected herein. Unless statedotherwise, or implicit from context, the following terms and phrasesinclude the meanings provided below. Unless explicitly stated otherwise,or apparent from context, the terms and phrases below do not exclude themeaning that the term or phrase has acquired in the art to which itpertains. The definitions are provided to aid in describing particularembodiments, and are not intended to limit the claimed invention,because the scope of the invention is limited only by the claims.Further, unless otherwise required by context, singular terms shallinclude pluralities and plural terms shall include the singular.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as those commonly understood to one of ordinaryskill in the art to which this invention pertains. Although any knownmethods, devices, and materials may be used in the practice or testingof the invention, the methods, devices, and materials in this regard aredescribed herein.

Other than in the operating examples, or where otherwise indicated, allnumbers expressing quantities of ingredients or reaction conditions usedherein should be understood as modified in all instances by the term“about.” The tern “about” when used to described the present invention,in connection with percentages means ±1%, ±1.5%, ±²%, ±2.5%, ±3%, ±1,5%,±4%, ±4.5%, or ±5%. The term “about” when used in connection withpercentages may mean ±1%, ±1.5%, ±2%, ±2.5%, ±3.5%, ±4%, ±4.5%, or ±5%of the value being referred to. [001.62] The singular terms “a,” “an,”and “the” include plural referents unless context clearly indicatesotherwise. Similarly, the word “or” is intended to include “and” unlessthe context clearly indicates otherwise.

As used herein the terms “comprising” or “comprises” means “including”or “includes” and are used in reference to compositions, methods,systems, and respective components) thereof, that are useful to theinvention, yet open to the inclusion of unspecified elements, whetheruseful or not.

As used herein the term “consisting essentially of” refers to thoseelements required for a given embodiment. The term permits the presenceof additional elements that do not materially affect the basic and novelor functional characteristic(s) of that embodiment of the invention.

The term “consisting of” refers to compositions, methods, systems, andrespective components thereof as described herein, which are exclusiveof any element not recited in that description of the embodiment.

The abbreviation, “e.g.” is derived from the Latin exempli gratia, andis used herein to indicate a non-limiting example. Thus, theabbreviation “e.g.” is synonymous with the term “for example.”

The terms “decrease”, “reduced”, “reduction”, “decrease” or “inhibit”are all used herein generally to mean a decrease by a statisticallysignificant amount. However, for avoidance of doubt, “reduced”,“reduction” or “decrease” or “inhibit” means a decrease by at least 10%as coinapared to a reference level, for example a decrease by at leastabout 20%, or at least about 30%, or at least about 40%, or at leastabout 50%, or at least about 60%, or at least about 70%, or at leastabout 80%, or at least about 90% or up to and. including a 100% decrease(e.g. absent level as compared to a reference sample), or any decreasebetween 10-100% as compared to a reference level.

The terms “increased”, “increase” or “enhance” or “activate” are allused herein to generally mean an increase by a statically significantamount; for the avoidance of any doubt, the terms “increased”,“increase” or “enhance” or “activate” means an increase of at least 10%as compared to a reference level, for example an increase of at leastabout 20%, or at least about 30%, or at least about 40%, or at leastabout 50%, or at. least about 60%, or at least about 70%, or at leastabout 80%, or at least about 90% or up to and including a 100% increaseor any increase between 10-100% as compared to a reference level, or atleast about a 2-fold, or at least about a 3-fold, or at least about a4-fold, or at least about a 5-fold or at least about a 10-fold increase,or any increase between 2-fold and 10-fold or greater as compared to areference level.

The term “statistically significant” or “significantly” refers tostatistical significance. and generally means at least two standarddeviation (2SD) away from a reference level. The term refers tostatistical evidence that there is a difference. It is defined as theprobability of making a decision to reject the null hypothesis when thenull hypothesis is actually true.

The term “derivative” as used herein refers to a chemical substancerelated structurally to another, i.e., an “original” substance, whichcan be referred to as a “parent” compound. A “derivative” can be madefrom the structurally-related parent compound in one or more steps. Insome embodiments, the general physical and chemical properties of aderivative can be similar to or different from the parent compound.

The term “alkyl” refers to saturated non-aromatic hydrocarbon chainsthat may be a straight chain or branched chain, containing the indicatednumber of carbon atoms (these include without limitation methyl, ethyl,propyl, iso-propyl, butyl, 2-methyl-ethyl, t-butyl, allyl, orpropargyl), which may be optionally inserted with N, O, or S. Forexample, C₁-C₆ indicates that the group may have from 1 to 6 (inclusive)carbon atoms in it.

The term “alkenyl” refers to an alkyl that comprises at least one doublebond. Exemplary alkenyl groups include, but are not limited to, forexample, ethenyl, propenyl, butenyl,1-methyl-2-buten-1-yl and the like.

The term “alkynyl” refers to an alkyl that comprises at least one triplebond.

The term “aryl” refers to monocyclic, bicyclic, or tricyclic aromaticring system wherein 0, 1, 2, 3, or 4 atoms of each ring may besubstituted by a substituent. Examplary aryl groups include, but are notlimited to, benzyl, phenyl, naphthyl, anthracenyl, azulenyl, fluorenyl,indanyl, indenyl, naphthyl, phenyl, tetrahydronaphthyl, and the like.

The term “cyclyl” or “cycloalkyl” refers to saturated and partiallyunsaturated cyclic hydrocarbon groups having 3 to 12 carbons, forexample, 3 to 8 carbons, and, for example, 3 to 6 carbons, wherein thecycloalkyl group additionally may be optionally substituted. Exemplarycycloatkyl groups include, but are not limited to, cyclopropyl,cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl,cycloheptyl, cyclooctyl, and the like.

The term “heteroaryl” refers to an aromatic 5-8 membered monocyclic,8-1.2 membered bicyclic, or 11-14 membered tricyclic ring system having1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9heteroatoms if tricyclic, said heteroatoms selected from O, N, or S(e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S ifmonocyclic bicyclic, or tricyclic, respectively), wherein 0, 1, 2., 3,or 4 atoms of each ring may be substituted by a substituent. Examplaryheteroaryl groups include, but are not limited to, pyridyl, furyl orfuranyl benzimidazolyl, pyrimidinyl, thiophenyl or thienyl, pyridazinyl,pyrazinyl, quinolinyl, indolyl, thiazolyl, naphthyridinyl, and the like.

The term “heterocyclyl” refers to a nonaromatic 5-8 membered monocyclic,8-12 membered bicyclic, or 11-14 membered tricyclic ring system having1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9heteroatoms if tricyclic, said heteroatoms selected from O, N, or S(e.g., carbon atoms and 1-3, 1.-6, or 1-9 heteroatoms of N, O, or S ifmonocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2 or 3atoms of each ring may be substituted by a substituent. Examplaryheterocyclyl groups include, but are not limited to piperazinyl,pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl, and the like.

The term “optionally substituted” means that the specified group ormoiety, such as an alkyl group, alkenyl group, and the like, isunsubstituted or is substituted with one or more (typically 1-4substituents) independently selected from the group of substituentslisted below in the definition for “substituents” or otherwisespecified.

The term “substituents” refers to a group “substituted” on thesubstituted entity (e.g., an alkyl, alkenyl, alkynyl, cycloalkyl aryl,heterocyclyl, or heteroaryl group) at any atom of that entity. Suitablesubstituents include, without limitation, halogen, hydroxy, oxo, nitro,haloalkyl, alkyl, alkenyl, alkynyl, alkaryl, aryl, aralkyl, alkoxy,aryloxy, amino, acylamino, alkylcarbanoyl, arylcarbanoyl, aminoalkyl,alkoxycarbanyl, carboxy, hydroxyalkyl, alkanesulfonyl, arenesulfonyl,alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl,acyloxy, cyano or ureido. In some cases, two substituents, together withthe carbons to which they are attached to can form a ring.

In some embodiments, the substituent group is selected from alkyl,ester, amide, monocarbonyl, dicarbonyl, ketones, aldehydes, and thelike.

As used herein, the term “epitope” means that portion of protein that isrecognized by a particular antibody. As such, the term “epitope”designates a specific amino acid sequence, modified amino acid sequence,or protein secondary or tertiary structure which is recognized by anantibody.

As used herein, the term “anti-cancer activity” or “anti-cancerproperties” refers to the inhibition (in part or in whole) or preventionof unregulated cell growth and/or the inhibition (in part or in whole)or prevention of a cancer as defined herein. Anticancer activityincludes, e.g., the ability to reduce, prevent, or repair geneticdamage, modulate undesired cell proliferation, modulate misregulatedcell death, or modulate mechanisms of metastasis (e.g., ability tomigrate).

As used herein, the term “cancer” refers to an uncontrolled growth ofcells that may interfere with the normal functioning of the bodilyorgans and systems. Cancers that migrate from their original locationand seed vital organs can eventually lead to the death of the subjectthrough the functional deterioration of the affected organs. Ametastasis a cancer cell or group of cancer cells, distinct from theprimary tumor location resulting from the dissemination of cancer cellsfrom the primary tumor to other parts of the body. At the time ofdiagnosis of the primary tumor mass, the subject may be monitored forthe presence of in transit metastases, e.g., cancer cells in the processof dissemination. As used herein, the term cancer, includes, but is notlimited to the following types of cancer, breast cancer, biliary tractcancer, bladder cancer, brain cancer including Glioblastomas andmedulloblastomas; cervical cancer; choriocarcinoma; colon cancer;endometrial cancer; esophageal cancer, gastric cancer; hematologicalneoplasms including acute lymphocytic and myelogenous leukemia; T-cellacute lymphoblastic leukernia/lymphoma; hairy cell leukemia; chronicmyelogenous leukemia, multiple myeloma; AIDS-associated leukemias andadult T-cell leukemia lymphoma; intraepithelial neoplasms includingBowen's disease and Paget's disease; liver cancer; lung cancer;lymphomas including Hodgkin's disease and lymphocytic lymphomas;neuroblastomas; oral cancer including squamous cell carcinoma; ovariancancer including those arising from epithelial cells, stromal cells,germ cells and mesenchymal cells; pancreatic cancer; prostate cancer;rectal cancer; sarcomas including leiomyosarcoma, rhabdomyosarcoma,liposarcoma, fibrosarcoma, and osteosarcoma; skin cancer includingmelanoma, Merkel cell carcinoma, Kaposi's sarcoma, basal cell carcinoma,and squamous cell cancer; testicular cancer including germinal tumorssuch as seminoma, non-seminoma (teratomas, choriocarcinomas), stromaltumors, and germ cell tumors; thyroid cancer including thyroidadenocarcinoma and medullar carcinoma; and renal cancer includingadenocarcinoma, Wilms tumor. Examples of cancer include but are notlimited to, carcinoma, including adenocarcinoma, lymphoma, blastoma,melanoma, sarcoma, and leukemia. More particular examples of suchcancers include squamous cell cancer, small-cell lung cancer, non-smallcell lung cancer, gastrointestinal cancer, Hodgkin's and non-Hodgkin'slymphoma, pancreatic cancer, Glioblastoma, cervical cancer, ovariancancer, liver cancer such as hepatic carcinoma and hepatoma, bladdercancer, breast cancer, colon cancer, colorectal cancer, endometrialcarcinoma, salivary gland carcinoma, kidney cancer such as renal cellcarcinoma and Wilms' tumors, basal cell carcinoma, melanoma, prostatecancer, vulval cancer, thyroid cancer, testicular cancer, esophagealcancer, and various types of head and neck cancer. Other cancers will beknown to the artisan.

As used herein, the term “cancer” includes, but is not limited to, solidtumors and blood born tumors. The term cancer refers to disease of skin,tissues, organs, bone, cartilage, blood and vessels. The term “cancer”further encompasses primary and metastatic cancers. Examples of cancersthat can be treated with the compounds of the invention include, but arenot limited to, carcinoma, including that of the bladder, breast, colon,kidney, lung, ovary, pancreas, stomach, cervix, thyroid, and skin,including squamous cell carcinoma; hematopoietic tumors of lymphoidlineage, including, but not limited to, leukemia, acute lymphocyticleukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-celllymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma,and Burketts lymphoma; hematopoietic tumors of mycloid lineageincluding, but not limited to, acute and chronic myelogenous leukemiasand promyelocytic leukemia; tumors of mesenchymal origin including, butnot limited to, fibrosarcoma, rhabdomyosarcoma, and osteosarcoma; othertumors including melanoma, seminoma, tetratocarcinoma, neuroblastoma,and glioma; tumors of the central and peripheral nervous systemincluding, but not limited to, astrocytoma, neuroblastoma, glioma, andschwannomas; and other tumors including, but not limited to, xenoderma,pigmentosum, keratoactanthoma, thyroid follicular cancer, andteratocarcinoma. The compounds of the invention are useful for treatingpatients who have been previously treated for cancer, as well as thosewho have not previously been treated for cancer. Indeed, the methods andcompositions of this invention can be used in first-line and second-linecancer treatments.

In some embodiments, the cancer or metastasis is selected from the groupconsisting of platinum susceptible or resistant tumors including breast,head and neck, ovarian, testicular, pancreatic, oral-esophageal,gastrointestinal, liver, gall bladder, lung. melanoma, skin cancer,sarcomas, blood cancers, brain tumors including glioblastomas, andtumors, of neuroectodermal origin.

As used herein, the term “precancerous condition” has its ordinarymeaning, i.e., an unregulated growth without metastasis, and includesvarious forms of hyperplasia and benign hypertrophy. Accordingly, a“precancerous condition” is a disease, syndrome, or finding that, ifleft untreated, can lead to cancer. It is a generalized state associatedwith a significantly increased risk of cancer. Premalignant lesion is amorphologically altered tissue in which cancer is more likely to occurthan its apparently normal counterpart. Examples of pre-malignantconditions include, but are not limited to, oral leukoplakia, actinickeratosis (solar keratosis), Barrett's esophagus, atrophic gastritis,benign hyperplasia of the prostate, precancerous polyps of the colon orrectum, gastric epithelial dysphasia, adenomatous dysplasia, hereditarynonpolyposis colon cancer syndrome (HNPCC), Barrett's esophagus, bladderdysplasia, precancerous cervical conditions, and cervical dysplasia.

As used herein, amino acids include natural or unnatural amino acids.Thus, as used herein, the term “amino acid” includes compounds whichdepart from the structure of the naturally occurring amino acids, butwhich have substantially the structure of an amino acid, such that theycan be substituted within a peptide which retains is activity, e.g.,biological activity. Thus, for example, in some embodiments amino acidscan also include amino acids having side chain modifications orsubstitutions, and also include related organic acids, amides or thelike. Without limitation, an amino acid can be a proteogenic ornon-proteogenic amino acid. As used herein, the term “proteogenic”indicates that the amino acid can be incorporated into a protein in acell through well-known metabolic pathways. Exemplary amino acidsamenable to the present invention include, but are not limited to,alanine; argnine; asparagine; aspartic acid; cysteine; glutamic acid;glutamine; glycine; histadine; isoleucine; leucine; lysine; methionine;phenylalanine; proline; serine; threonine; tryptophan; tyrosine; valine;homocysteine; phosphoserine; phosphothreonine; phosphotyrosine;hydroxyproline; γ-carboxyglutamate; hippuric acid;octahydroindole-2-carboxylic acid; statine;1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; penicillamine(3-mercapto-D-valine); ornithine (Orn); citruline; alpha-methyl-alanine;para-benzoylphenylalanine; para-aminophenylalanine;p-fluorophenylalanine; phenylglycine; propargylglycine; N-methylglycins(sarcosine, Sar); and tert-butylglycine; diaminobutyric acid;7-hydroxy-tetrahydroisoquinoline carboxylic acid; naphthylalanine;biphenylalamine; cyclohexylalanine; amino-isobutyric acid (Aib);norvaline; norleucine (Nle); tort-leucine; tetrahydroisoquinolinecarboxylic acid; pipecolic acid; phenylglycine; homophenylalanine;cyclohexylglycine; dehydroleucine; 2,2-diethylglycine;1-amino-1-cyclopentanecarboxylic acid; 1-amino-1-cyclohexanecarboxylicacid; amino-benzoic acid; amino-naphthoic acid; gamma-aminobutyric acid;difluorophenylalanine; nipecotic acid; N-α-imidazole acetic acid (IMA);thienyl-alanine; t-butylglycine; desamino-Tyr; aminovaleric acid (Ava);pyroglutaminic acid (<Glu); α-aminoisobutyric acid (αAib);γ-aminobutyric acid (γAbu); α-aminobutyric acid (αAbu); αγ-aminobutyricacid (αγAbu); 3-pyridylalanine (Pal); Isopropyl-α-N^(c)-lysine (ILys);Napthyalanine (Nal); α-napthyalanine (α-Nal); β-napthyalanine (β-Nal);Acetyl-β-napthyalanine (Ac-β-napthyalanine); napthyalanine;N^(ε)-picoloyl-lysine (PicLys); 4-halo-Phenyl; 4-pyrolidylalanine;isonipecotic carboxylic acid (inip); beta-amino acids; and isomers,analogs and derivatives thereof. One of skill in the art would know thatthis definition includes, D- and L-amino acids, alpha- and beta-aminoacids, chemically modified ammo acids, naturally occurringnon-proteogenic amino acids, rare amino acids, and chemicallysynthesized compounds that have properties known in the art to becharacteristic of an amino acid.

Peptide modifications are well known in the art. Thus, a peptidedescribed herein, e.g., a linker peptide, can comprise one or morepeptide modifications known in the art. Exemplary peptide modificationsfor modifying the fusion protein described herein include, but are notlimited to, D amino acids, α amino acids, β amino acids, non-amide ormodified amide linkages, chemically modified amino acids, naturallyoccurring non-proteogenic amino acids, rare amino acids, chemicallysynthesized compounds that have properties known in the art to becharacteristic of an amino acid, and the like. Thus, as used herein,peptide includes natural or unnatural amino acids, or a combinationthereof.

As used herein, the term “PEG” means an ethylene glycol polymer thatcontains about 20 to about 2000000 linked monomers, typically about50-1000 linked monomers, usually about 100-300. Polyethylene glycolsinclude PEGs containing various numbers of linked monomers, e.g., PEG20,PEG30, PEG40, PEG60, PEG80, PEG100, PEG115, PEG200, PEG 300, PEG400,PEG500, PEG600, PEG1000, PEG1500, PEG2000, PEG3350, PEG4000, PEG4600,PEG5000, PEG6000, PEG8000, PEG11000, PEG12000, PEG2000000 and anymixtures thereof.

Embodiments of the various aspects described herein can also bedescribed by any one of the following paragraphs.

-   1. A ligand-targeted molecule comprising:    -   (i) a functional moiety;    -   (ii) a linker connected to said functional moiety;    -   (iii) a dicarbonyl moiety connected to said linker; and    -   (iv) a drug connected to said dicarbonyl moiety;

wherein said drug is a platinum chemotherapeutic agent.

-   2. The ligand-targeted molecule of paragraph 1 wherein said platinum    chemotherapeutic agent are Pt(II) chemotherapeutic agents.-   3. The ligand-targeted molecule of any of paragraphs 1-2, wherein    said platinum chemotherapeutic agent is cisplatin, oxaliplatin,    carboplatin or other Pt(II) agents,-   4. The ligand-targeted molecule of any of paragraphs 1-3, wherein    said functional moiety is thiol reactive, amine reactive or azide    reactive.-   5. The ligand-targeted molecule of any of paragraphs 1-4, wherein    said functional moiety is maleimide.-   6. The ligand-targeted molecule of any of paragraphs 1-5, wherein    said linker is a hydrocarbon, polyethylene glycol (PEG), an amino    acid, a peptide, or a combination thereof, said hydrocarbon or PEG    being substituted or unsubstituted.-   7. The ligand-targeted molecule of paragraph 6, wherein said linker    is a hydrocarbon.-   8. The ligand-targeted molecule of paragraph 6, wherein said linker    is PEG.-   9. The ligand-targeted molecule of paragraph 8, wherein said PEG has    a molecular weight of between from about 200 Da to about 50 kDa.-   10. The ligand-targeted molecule of any of paragraphs 1-9, wherein    said linker comprises a combination of at least one amino acid and    substituted or unsubstituted PEG.-   11. The ligand-targeted molecule of paragraph 10 wherein said amino    acid is lysine.-   12. The ligand-targeted molecule of any of paragraphs 1-11, wherein    said linker comprises a combination of two amino acids and    substituted or un substituted PEG.-   13. The ligand-targeted molecule of any of paragraphs 1-11, wherein    said linker comprises a combination of three amino acids and    substituted or unsubstituted PEG.-   14. The ligand-targeted molecule of any of paragraphs 1-13, wherein    said dicarboxyl moiety is succinate-   15. The ligand-targeted molecule of paragraph 14 wherein said    dicarbonyl moiety is succinate.-   16. A ligand drug conjugate comprising a ligand connected to a    ligand-targeted molecule, wherein said ligand-targeted molecule    comprises a functional moiety, at least one linker connected to said    functional moiety, a dicarbonyl moiety connected to said linker, and    a drug connected to said dicarbonyl moiety, said drug being a    platinum chemotherapeutic agent, and said ligand being connected to    said functional moiety.-   17. The ligand drug conjugate of paragraph 16 wherein said ligand is    an antibody, antibody fragment, peptide, agonist, antagonist or    aptamer.-   18, The ligand drug conjugate of any of paragraphs 16-17, wherein    said ligand is an antibody.-   19. The ligand drug conjugate of paragraph 18 wherein said antibody    is targeted to the Epidermal Growth Factor Receptor.-   20 The ligand drug conjugate of paragraph 19 wherein said antibody    is connected to said functional moiety through a thioether bond.-   21. A ligand drug conjugate comprising a ligand connected to a    ligand-targeted molecule, wherein said ligand-targeted molecule    comprises a functional moiety, at least one linker connected to said    functional moiety, a first drug connected to said linker, a    dicarbonyl moiety connected to said linker, and a second drug    connected to said dicarbonyl moiety, said second drug being a    platinum compound, and said ligand being connected to said    functional moiety.-   22. The conjugate of paragraph 21, wherein said first drug is an    anti-cancer agent.-   23. The conjugate of paragraph 22, wherein said anti-cancer agent is    selected from the group consisting of Maytansinoid (DM1 and DM4);    CC-1065; Adozelesin (DC1); DC4; Calicheamicins; Dolastatins:    Auristatins E and F; Meamycin; Doxorubucin; Paclitaxel; Docetaxel;    Laulimalide; Epothilones A and B; Discodermolide; Eleutherobin;    Peloruside A; cyclophosphamide, chlorambucil, uramustine,    ifosfamide, melphalan, and bendamustine; Carmustine, lomustine,    semustine; Busulfan; Thiotepa; Dacarbazine; Methotrexate;    6-mercaptopurine, 6-thioguanine, pentostatin, fludarabine;    5-fluorouracil, cytarabine, leukovorin; Dactinomycin; Bleomycin;    Daunorubicin; Mitomycin; Idarubicin; Plicamycin; Vincristine;    Vinblastine; Vinorelbine; Etoposide; Teniposide; Asparaginase;    Maitotoxin; Irinotecan (CPT-11); Fumagillin; Fumagalone; Fumarranol;    O-(Chloroacetylcarbamoyl)-Fumagillol (AGM-1470 TNP-470);    27-hydroxybullatacin, derivatives and analogues thereof, and any    combinations thereof.-   24. The conjugate of any of paragraphs 21-23, wherein said platinum    compound is a platinum (11) compound.-   25. The conjugate of paragraph 24, wherein said platinum (II)    compound is selected from the group consisting of cisplatin,    carboplatin, paraplatin, sartraplatin, and combinations thereof.-   26. The conjugate of any of paragraphs 21-25, wherein said ligand    binds a protein, receptor, or cell marker on a surface of a cancer    cell.-   27. The conjugate of any of paragraphs 21-26, wherein said ligand    hinds Epidermal Growth Factor Receptor.-   28. The conjugate of any of paragraphs 21-27, wherein said ligand is    an antibody, antibody fragment, peptide, agonist, antagonist or    aptamer.-   29. The conjugate of paragraph 28, wherein said antibody is selected    from the group consisting of C242 antibody (CanAg), Rituximab,    Trastuzumab (Her2), Cetuximab, Bevacizumab (VEGF), Panitumumab,    Ofatumumab, Gemtuzumab (CD33), Inotuzumab (CD22), Lorvotuzumab    (CD56), Brentuximab (CD30), Glembatumumab (GPNMB), epitope bind    fragments thereof and any combinations thereof.-   30. The conjugate of any of paragraphs 21-29, wherein said linker is    a hydrocarbon., polyethylene glycol (PEG), an amino acid, a peptide,    or a combination thereof, said hydrocarbon or PEG being substituted    or unsubstituted.-   31. The conjugate of paragraph 30, wherein said linker is a    hydrocarbon.-   32. The conjugate of paragraph 30, wherein said linker is PEG.-   33. The conjugate of paragraph 32, wherein said PEG has a molecular    weight of between from about 200 Da to about 50 kDa.-   34. The conjugate of any of paragraphs 21-33, wherein said linker    comprises a combination of at least one amino acid and substituted    or unsubstituted. PEG.-   35. The conjugate of paragraph 34 wherein said linker comprises two    or three amino acids.-   36. The conjugate of paragraph 34, wherein said amino acid is    lysine.-   37. The conjugate of any of paragraphs 21-36, wherein said    dicarbonyl moiety is succinate.-   38. The conjugate of paragraph 37, wherein said dicarbonyl moiety is    succinate.-   39. A ligand drug conjugate comprising a ligand connected to a    ligand-targeted molecule, wherein said ligand-targeted molecule    comprises a functional moiety, at least one first linker connected    to said functional moiety, a coordination metal complex connected to    said first linker, at least one second linker connected to said    coordination metal complex, a drug connected to said second linker,    and said ligand connected to said functional moiety.-   40. The conjugate of paragraph 39, wherein said coordination metal    complex comprises a O→metal coordination bond.-   41. The conjugate of any of paragraphs 39-40, wherein said O→metal    coordination bond is with amide carbonyl oxygen or ester carbonyl    oxygen.-   42. The conjugate of any of paragraphs 39-41, wherein said    coordination metal complex is a platinum, iron, or silicon complex.-   43. The conjugate of any of paragraphs 39-42, wherein said    coordination metal complex is a platinum (II) complex.

44. The conjugate of paragraph 43, wherein said platinum (11) complex is

wherein b is 0, 1, 2, 3, 4, or 5 and R⁵ is a cyclic or acyclic linkerjoining the two amino groups to the first or the second linker;

wherein c is 0, 1, 2, 3, 4, or 5 and R⁶ is a cyclic or acyclic linkerjoining the two amino groups to first or the second linker;

wherein d is 0, 1., 2, 3, 4, or 5 and the two amines are linked todifferent first or second linkers;

wherein e is 0, 1, 2, 3, 4, or 5, and the two amines are linked todifferent first or second linkers;

wherein f is 0, 1, 2, 3, 4, or 5 and R⁷ is a cyclic or acyclic linkerjoining the two amino groups to the first or the second linker;

wherein g is 0, 1, 2, 3, 4, or 5 and R⁸ is a cyclic or acyclic linkerjoining the two amino groups to the first or the second linker; or

wherein R⁹ is a cyclic or acyclic linker joining the two amino groups tothe first or the second linker.

-   45. The conjugate of paragraph 44, wherein said platinum (II)    complex is

wherein b is 0. 1, 2, 3, 4, or 5;

wherein c is 0, 1, 2, 3, 4, or

wherein f is 0, 1, 2, 3, 4, or 5; or

wherein g is 0, 1, 2, 3, 4, or 5.

-   46. The conjugate of paragraph 44, wherein said platinum (II)    complex is

-   47. The conjugate of any of paragraphs 39-46, wherein said drug is    an anti-cancer agent.-   48. The conjugate of paragraph 47, wherein said anti-cancer agent is    selected from the group consisting of Maytansinoid (DM1 and DM4);    CC-1065; Adozeiesin (DC1); DC4; Calicheamicins; Doiastatins;    Auristatins E and F; Meamycin; Doxorubucin; Paclitaxel; Docetaxel;    Laulimalide; Epothilones A and B; Discodermolide; Eleutherobin;    Peloruside A; cyclophosphamide, chlorambucil, uramustine,    ifosfamide, melphalan, and bendamustine; Carmustine, lomustine,    semustine; Busulfan; Thiotepa; Dacarbazine; Methotrexate;    6-mercaptopurine, 6-thioguanine, pentostatin, fludarabine;    5-fluorouracil, cytarabine, leukovorin; Dactinomycin; Bleomycin;    Daunorubicin; Mitomycin; Idarubicin; Plicamycin; Vincristine;    Vinblastine; Vinorelbine; Etoposide; Teniposide; Asparaginase;    Maitotoxin; Irinotecan (CPT-11); Fumagillin; Fumagalone; Fumarranol;    O-(Chloroacetylcarbamoyl)-Fumagillol (AGM-1470, TNP-470);    27-hydroxybullatacin, derivatives and analogues thereof, and any    combinations thereof.-   49. The conjugate of any of paragraphs 39-48, wherein said ligand    binds a protein, receptor, or cell marker on a surface of a cancer    cell.-   50. The conjugate of any of paragraphs 39-49, wherein said ligand    binds Epidermal Growth Factor Receptor.-   51. The conjugate of any of paragraphs 39-50, wherein said ligand is    an antibody, antibody fragment, peptide, agonist, antagonist or    aptamer.-   52. The conjugate of paragraph 51, wherein said antibody is selected    from the group consisting of C242 antibody (CanAg), Rituximab,    Trastuzumab (Her2), Cetuximab, Bevacizumab (VEGF), Panitumumab,    Alemtuzumab, Ofatumumab, Gemtuzumab (CD33), Inotuzumab (CD22),    Lorvotuzumab (CD56), Brentuximab (CD30), Glembatumumab (GPNMB),    epitope bind fragments thereof and any combinations thereof.-   53. The conjugate of any of paragraphs 39-52, wherein said first or    second linker is a hydrocarbon, polyethylene glycol (PEG), an amino    acid, a peptide, or a combination thereof, said hydrocarbon or PEG    being substituted or unsubstituted.-   54. The conjugate of paragraph 53, wherein said first or second    linker is a hydrocarbon,-   55. The conjugate of paragraph 53, wherein said first or second    linker is PEG.-   56. The conjugate of paragraph 55, wherein said PEG has a molecular    weight of between from about 200 Da to about 50 kDa.-   57. The conjugate of any of paragraphs 39-56, wherein said first or    second linker comprises a combination of at least one amino acid and    substituted or unsubstituted PEG.-   58. The conjugate of paragraph 57, wherein said first or second    linker comprises two or three amino acids.-   59. The conjugate of paragraph 58, wherein said amino acid is    lysine.-   60. A pharmaceutical composition comprising a conjugate of paragraph    1 and a pharmaceutically acceptable carrier.-   61. A pharmaceutical composition comprising a conjugate of paragraph    16 and a pharmaceutically acceptable carrier.-   62. A pharmaceutical composition comprising a conjugate of paragraph    21 and a pharmaceutically acceptable carrier.-   63. A pharmaceutical composition comprising a conjugate of paragraph    39 and a pharmaceutically acceptable carrier.-   64. A method of treating a cancer in a subject in need thereof, the    method comprising administering an effective amount of a conjugate    of paragraph 1.-   65. A method of treating a cancer in a subject in need thereof, the    method comprising administering an effective amount of a conjugate    of paragraph 16.-   66. A method of treating a cancer in a subject in need thereof, the    method comprising administering an effective amount of a conjugate    of paragraph 21.-   67. A method of treating a cancer in a subject in need thereof, the    method comprising administering an effective amount of a conjugate    of paragraph 39.

The disclosure is further illustrated by the following examples whichshould not be construed as limiting. The examples are illustrative only,and are not intended to limit, in any manner, any of the aspectsdescribed herein. The following examples do not in any way limit theinvention.

EXAMPLES Example 1 Synthesis of a Hydrocarbon-Linker Pt(II) ConjugateSynthesis of a Maleimide-Hydrocarbon With Blocked Lysine Intermediate(2)

To an ice cooled solution of 6-malimidocaproic acid (1) in CH₂Cl₂ (5 mL)under nitrogen atmosphere, EDCI (544.5 mg, 2.8407 mmol) and HOBT (383.7mg, 2.8407 mmol was added successively and stirred for 1 h. To thisactivated acid solution, protected lysine (630 mg, 2.1305 mmol) wasadded. The reaction mixture was basified with DIPEA and stirred for 12 hat room temperature, and analysed by TLC. After completion, the reactionmixture was quenched with H₂O (10 mL) and twice with 0.1N HCl (25 mL),the intermediate compound 2 was extracted with twice with CHCl₃ (15 mLeach). The combined organic layer was dried over anhydrous Na₂SO₄,concentrated under reduced pressure and purified by silica gelchromatography to obtain coupling product 2 with 93% yield (602 mg).

¹H NMR (500 MHz. CDCl₃) δ: 6.71 (s, 2H), 6.07 (d, J=7.1 Hz, 1H), 4.61(dt, J=12.8, 6.5 Hz, 1H), 3.76 (s, 3H), 3.53 (dd, J=14.1, 6.9 Hz, 2H),3.12 (s, 2H), 2.33-2.15 (m, 2H), 1.92-1.80 (m, 2H), 1.78-1.57 (m, 4H),1.56-1.48 (m, 2H), 1.48-1.41 m, (m, 11H), 1.41-1.24 (m, 2H). ESIMSm/z=476 [M+Na]⁺for C₂₂H₃₅N₃O₇Na.

Synthesis of Maleimide-Hydrocarbon With Activated Lysine Intermediate(3)

Next, to an ice cooled solution of intermediate 2 (450 mg, 0.9922 mmol)in CH₂Cl, (4 mL), 1 ml TFA was added, stirred on ice for 3 h, andanalysed by TLC. Upon completion of the reaction, the mixture wasconcentrated under reduced pressure to obtain intermediate 3 with aquantitative yield. This intermediate was directly used for the nextcoupling reaction without further purification

Synthesis of Hydrocarbon-Lysine-Succinate Intermediate (4)

The crude starting material 3 was mixed in DMF at a 1:4 ratio, andCH₂Cl₂ (1:4 mL) at 0° C. under nitrogen atmosphere. The solution wasbasified with DIPEA (pH was checked), stirred for 30 minutes on ice.Succinic anhydride (250 mg, 2.5 mmol) was added to the reaction mixture,stirred for 12 h and checked by TLC. After completion, the reactionmixture was quenched with H₂O (10 mL) and twice with 0.1N HCl (25 mLeach), extracted twice with CHCl₃ (15 mL each). The combined organiclayer was dried over anhydrous Na₂SO₄, concentrated under reducedpressure and purified by silica gel chromatography to obtain acidintermediate 4 in with limited yield (90 mg, 20% yield).

¹H NMR (500 MHz, CDCl₃) δ: 6.72 (s, 2H), 6.45 (d, J=7.9 Hz, 1H), 6.35(s, 1H), 4.62. (td, J=8.2, 4.6 Hz, 1H), 3.7 (s, 3H), 3.53 (dd, J=14.0,6.9 Hz, 2H), 3,37-3.24 (m, 2H), 2.81-2.64 (m, 2H), 2.58-2.48 (m, 2H),2.28 (t, J=7.4 Hz, 2H), 1.84 (td, J=12.6, 7.8 Hz, 2H), 1.76-1.50 (m,4H), 1.47-1.19 (m, 6H). ESIMS m/z=454 [M+H]^(30 for C) ₂₁H₃₁N₃O₈.

Synthesis of Linker Conjugated Platinum (II) Complex (Ligand-TargetedMolecule, 6)

Intermediate 4 (48 mg, 0.105 mmol) was taken in 0.5 mL DMF. To this 3.0mL of aquated oxaliplatin (5) [5 mg/mL, 1.0 equiv] was added slowly atroom temperature, stirred for 24 h at room temperature. The reactionmixture was finally lyophilized to completely remove the solventresulting in final product 6 with quantitative yield and purity (80 mg,99%).

Example 2 Synthesis of a PEG-Linker Conjugated Platinum (II) DerivativeSynthesis of Maleimide-Poly(Ethylene)Glycol With Blocked LysineIntermediate 9):

To an ice cooled solution of Mal-PEG-SCM (7) [100 mg, ˜0.0454 mmol;Creative PEG Works] in anhydrous CH₂Cl₂ (3 mL) and DMF (2 mL) undernitrogen atmosphere, protected lysine (135 mg, 0.454 mmol) was added,the reaction mixture was basified with DIPEA (77 μL) and stirred at roomtemperature for 12 h, analysed by TLC. After completion of the reaction,the mixture was flushed with nitrogen for 5 minutes to remove traces ofCH₂Cl₂. The residue was diluted with Et₂O (40 mL) and stored at 4° C.for 45 min, and then centrifuged at low temperature. The clear solutionwas decanted, and the solid pellet was dissolved in a small volume ofmethanol and diluted with Et₂O (40 mL), incubated at 4° C. for 45minutes and centrifuged to get solid precipitate. The process wasrepeated twice to obtain pure coupling product 9 with a good yield (92mg, purity ??HPLC not done)

Synthesis of Maleimide-PEG With Activated Lysine Intermediate (10)

To an ice cooled solution of intermediate 9 (90 mg, ˜0.0367 mmol) inCH₂Cl₂ (4 mL), TFA (0.5 mL) was added, stirred on ice for 2.5 h andanalysed by TLC. After completion of the reaction, the mixture wasconcentrated under reduced pressure, flushed with nitrogen for 5 minutesto remove excess CH₂Cl₂ and TFA, and the residual product was directlyused for the next coupling reaction without further purification.

Synthesis of PEG-Lysine-Succinate Intermediate (12)

The crude starting material 10 was taken in 1:4 DMF and CH₂Cl₂ (1:4 mL)at 0° C. under nitrogen atmosphere. The solution was basified withDIPEA, and stirred for 30 minutes at the same temperature. Succinicanhydride 11 (2.00 mg, 2.0 mmol) followed by a pinch of DMAP was addedto the reaction mixture and stirred for 12 h and was checked by TLC.After completion the reaction mixture was flushed with nitrogen over 10minutes to remove CH₂Cl₂ and the residue was diluted with Et₂O (40 mL),incubated at 4° C. for 45 min, and then centrifuged at low temperature.The clear solution was decanted and the solid residue was dissolved inmethanol and diluted with Et₂O (40 mL), further inubated at 4° C. for 45minutes and centrifuged to get solid precipitate. This process wasrepeated twice to obtain crude coupling product which was furtherpurified by HPLC to obtain our desired product 12 with a good yield.

Synthesis of PEG-Linker Conjugated Platinum (II) Complex(Ligand-Targeted Molecule, 13)

Acid intermediate 12 (80 mg, (1032 mmol) was dissolved in 0.5 mL H₂O. Tothis solution actuated oxaliplatin (5 mg/mL, 1.0 equiv) was added slowlyat room temperature and stirred for another 24 h. The reaction mixturewas lyophilized to obtain platinum adduct 13 with good yield (80 mg).

Example 3 Conjugation of Drug-Linker Molecules to Antibodies

This example describes reaction conditions and methodologies forconjugating a drug-linker molecule of the invention (optionallyincluding other groups, such as spacers, reactive functional groups andthe like) to an antibody as a targeting agent. An the conditions andmethodologies employed are intended to be exemplary only andnon-limiting. One of skill in the art is well aware of reagents andmethods for conjugating molecules, e.g., linkers, drugs, and the like toantibodies.

The conjugation method employed is based on introduction of free thiolgroups to the antibody by reducing the inter-chain cysteines withreducing agents, followed by reaction of the drug-linker molecule withan active maleimide group. Towards this end, the antibody to beconjugated was buffer exchanged into PBS buffer pH 7.4 and concentratedto 8-10 mg/ml. The inter-chain cysteines were reduced by addition of DTTor 2-MEA to the antibody. The amount of reducing agent to be added wasdetermined in preliminary experiments. In the optimization experiments,a titration of increasing amounts of reducing agent was added to theantibody. After incubation with the antibody for one hour at 37° C. thepartially reduced antibody was purified and desalted of DTT or 2-MEA(Amicon Ultra, 30K MWCO). The number of thiol groups introduced wasdetermined by reaction with dithionitro benzoic acid (DTNB). Reaction ofthiol groups with DTNB results in a mixed disulfide and nitrothiobenzoic acid (TNB) product which is spectrophotometrically detected at412 nm. The concentration of protein in the samples was accuratelydetermined by the absorbance at 280 nm.

Typically a thiolation level of 4-6 thiol groups per antibody is optimalfor conjugation. For example, with one particular antibody this wasachieved through adding a 5 fold molar excess of DTT followed byincubation at 37° C. for 1 hour. Antibody to be conjugated was thereforeincubated with DTT at the desired molar ratio, then desalted intoconjugation buffer (PBS, pH7.4, 10 mM ETDA). The thiolated material wasmaintained on ice whilst the number of thiols introduced was quantitatedas described above.

To the mildly reduced antibody, the drug-linker molecule containing anactive maleimide group was added at a 30-fold molar excess per thiol.The linker-drug conjugate was dissolved in 10% (v/v) DMSO in. PBS forPBS buffer alone). This stock solution of drug-linker was added to thethiolated antibody.

The conjugation reaction was carried out over night at 4° C. in PBSbuffer with mixing. Next day, 3 ml PBS buffer was added to the reactionmix, then it was desalted and concentrated by diafiltration (AmiconUltra, 30K MWCO) by centrifuging at 2000×g for 15 minutes. This step wasrepeated at least 4 times, and finally the conjugate was analysed forprotein and platinum content by UV and atomic absorption spectroscopy.

Example 4 Binding of ADC on the Target Cell Surface Receptor

For testing EGFR receptor binding by the mAb-PEG-linker-Pt conjugate96-well microtiter Maxisorb plates (Nune, PIERCE) were coated with80-100 μl of 2 mg/L of EGFR-ECD (in PBS buffer) for overnight at 420 C.The wells were washed with PBST (PBS containing 0.1% Tween-20) andblocked with 2% Casein in PBS for 1-2 h at RT. The wells were furtherwashed with PBST as above and serially diluted antibody drug conjugate(ADC) was added to the respective wells, and incubated for 2 h at roomtemperature. After a final wash with PBST as above, the goat anti-humanIgG1-HRP antibody (1:10000 diluted) was added and incubated for 1 hr atroom temperature. Wells were washed and the PBTS reagent was added. Thecolour development was stopped by adding 100 μl of 1% SDS to each well.Reading of the plate was performed at 415 nm with a microplate reader(BioRad).

Example 5 Analysis of PEG Content on the ADC

The PEG content in the ADC was analysed by ELISA and SDS-PAGE. For theELISA. Maxisorp microtiter plate was coated with varying concentrationof ADC and incubated over night at 4° C. The wells were washed with washbuffer (PBS, 0.1% Tween-20) and blocked with 2% Casein/PBST for 2 h atroom temperature. After another wash as above, 70-100 μl of the mousebiotinylated anti-PEG monoclonal detection antibody (1:500-1000 diluted)was added to the wells, incubated for 1 h at room temperature. Wellswere washed again with PBST, 100 μl of streptavidin-HRP was added andincubated for 30-45 min. Finally, wells were washed with PBS and theABTS reagent was added. The colour development was stopped by adding 100μl of 1% SDS to each well, and plate was read at 415 nm.

The presence of PEG on the ADC was also qualitatively determined byrunning the samples on a 10% SDS-PAGE under reducing and non-reducingconditions.

Example 6 Analysis of the Cytotoxicity of the ADC

The cytotoxic potency of the anti-cancer platinum agents conjugated tothe antibody of the invention was assayed using the well established MTTcell proliferation assay. This is a convenient method for quantitatingcellular viability, and can accommodate large numbers of compounds.

For the MTT assay, the metastatic breast cancer cell line MDA-MB-231 andthe colorectal cell line HT-29 were cultured in DMEM media containing10% heat inactivated fetal calf serum (FCS), 2 mM L-glutamine, 50 IU/mLpenicillin and 50 μg/mL streptomycin.

For testing the Cetuximab-PEG linker-Pt or the Cetuximab-hydrocarbonlinker-Pt conjugates, cells were plated to 96-well microtiter plates(3000-5,000 cells/well), Serial dilutions (3 -fold increments) ofplatinum drug (as a positive control) or test compounds were made, and100 μl of compounds were added per well. The survival profile of thecells was measured with the MTT assay 96 hr after plating.

Example 7 Synthesis of Tri-Lysine Containing Ligand-Targeted MoleculeConjugated With Antibody

Trilysine containing ligand-targeted molecule conjugated with antibodycan be synthesized according to the method shown in FIGS. 12A and 12B.Shown is a schematic representation of the synthesis of a tri-lysinatedPt(II) analogs conjugated to the anti-EGFR monoclonal antibody. Reagentsand Conditions: a) HoBT, EDCI, Dry DCM, DIPEA, 12 h, rt; b) H2, Pd,Ethylacetate, 6 h, rt; c) HoBT, EDCI, Dry DCM, Na-Cbz-Ne-Boc-L-Lysine,d) H2, Pd, Ethylacetate, 6 h, rt; e) HoBT, EDCI, HOOC-PEG-Mal, Dry DCM,DIPEA, 12 h, rt; f) TFA, Dry DCM, 3 h, 0 oC; g) succinic anhydride,pyridine, Dry DCM, 12 h, rt; h) Cis-diamminedihydro platinum(II), DMF,H2O, 24 h, rt; i) Antibody-SH (EGFRmAb-SH).

Example 8 Synthesis of Ligand-Targeted Conjugates Using Pt (II) as Partof a Linker

A general process for the synthesis of a ADC using Pt(11) coordinationlinker drug complex is shown in FIGS. 13A and 13B. Step 1: Coupling of ametal chelator to the antibody by conjugating via the amine groups oflysine is carried out using the method outlined in FIG. 13A. Step 2:Conjugating a cytotoxic drug to the antibody-chelator complex throughPt(III) analogs is carried out according to the method outlined in FIG.13B.

Example 9 Synthesis of a ADC Using the Pt(II)-Coordination Linker toConjugate the Cytotoxic Drug 27 Hydroxybullatacin

Synthesis of a ADC using the Pt(II)-coordination linker to conjugate thecytotoxic drug 27-Hydroxybullatacin can be carried out using the methodoutlined in FIGS. 14A-14C. FIGS. 14A-14C show a schematic representationof the synthesis of an antibody conjugated to the cytotoxic drug27-hydoxybullatacin using Pt(II) coordination linker (steps 1-3). Step1: Synthesis of modified antibody is according to the method outlined inFIG. 14A. Steps 2 and 3 of the synthesis can be carried out as outlinedin FIGS. 14B and 14C respectively.

Example 10 Synthesis of a ADC Using the Pt(II)-Coordination Linker toConjugate the Cytotoxic Drug Meayamycin

Synthesis of a ADC using the Pt(II)-coordination linker to conjugate thecytotoxic drug meayamycin can be carried out using the method outlinedin FIGS. 15A-15C. FIGS. 15A-15C show a schematic representation of thesynthesis of an antibody conjugated to the cytotoxic meayamycin usingPt(II) coordination linker (steps 1-3).

All patents and other publications identified in the specification andexamples are expressly incorporated herein by reference for allpurposes. These publications are provided solely for their disclosureprior to the filing date of the present application. Nothing in thisregard should be construed as an admission that the inventors are notentitled to antedate such disclosure by virtue of prior invention or forany other reason. All statements as to the date or representation as tothe contents of these documents is based on the information available tothe applicants and does not constitute any admission as to thecorrectness of the dates or contents of these documents.

Although preferred embodiments have been depicted and described indetail herein, it will be apparent to those skilled in the relevant artthat various modifications, additions, substitutions, and the like canbe made without departing from the spirit of the invention and these aretherefore considered to be within the scope of the invention as definedin the claims which follow. Further, to the extent not alreadyindicated, it will be understood by those of ordinary skill in the artthat any one of the various embodiments herein described and illustratedcan be further modified to incorporate features shown in any of theother embodiments disclosed herein.

What is claimed:
 1. A ligand-targeted molecule comprising: a functionalmoiety; (ii) a linker connected to said functional moiety; (iii) adicarbonyl moiety connected to said linker; and (iv) a drug connected tosaid dicarbonyl moiety; wherein said drug is a platinum chemotherapeuticagent.
 2. The ligand-targeted molecule of claim 1 wherein saidfunctional moiety is thiol reactive, amine reactive or azide reactive.3. The ligand-targeted molecule of claim 1 wherein said linker is ahydrocarbon, polyethylene glycol (PEG), an amino acid, a peptide, or acombination thereof, said hydrocarbon or PEG being substituted orunsubstituted.
 4. The ligand-targeted molecule of claim 3 wherein saidlinker comprises a combination of at least one amino acid andsubstituted or unsubstituted PEG.
 5. The ligand-targeted molecule ofclaim 3 wherein said dicarbonyl moiety is succinate.
 6. A pharmaceuticalcomposition comprising a conjugate of claim 1 and a pharmaceuticallyacceptable carrier.
 7. A method of treating a cancer in a subject inneed thereof, the method comprising administering an effective amount ofa conjugate of claim
 1. 8. A ligand drug conjugate comprising a ligandconnected to a ligand-targeted molecule, wherein said ligand-targetedmolecule comprises a functional moiety, at least one linker connected tosaid functional moiety, a dicarbonyl moiety connected to said linker,and a drug connected to said dicarbonyl moiety, said drug being aplatinum chemotherapeutic agent, and said ligand being connected to saidfunctional moiety.
 9. The ligand drug conjugate of claim 8 wherein saidligand is an antibody, antibody fragment, peptide, agonist, antagonistor aptamer.
 10. The ligand drug conjugate of claim 9 wherein saidantibody is connected to said functional moiety through a thioetherbond.
 11. A pharmaceutical composition comprising a conjugate of claim 8and a pharmaceutically acceptable carrier.
 12. A method of treating acancer in a subject in need thereof, the method comprising administeringan effective amount of a conjugate of claim
 8. 13. A ligand drugconjugate comprising a ligand connected to a ligand-targeted molecule,wherein said ligand-targeted molecule comprises a functional moiety, atleast one linker connected to said functional moiety, a first drugconnected to said linker, a dicarbonyl moiety connected to said linker,and a second drug connected to said dicarbonyl moiety, said second drugbeing a platinum compound, and said ligand being connected to saidfunctional moiety.
 14. The conjugate of claim 13, wherein said firstdrug is an anti-cancer agent.
 15. The conjugate of claim 13, whereinsaid linker is a hydrocarbon, polyethylene glycol (PEG), an amino acid,a peptide, or a combination thereof, said hydrocarbon or PEG beingsubstituted or unsubstituted.
 16. The conjugate of claim 13, whereinsaid ligand is an antibody, antibody fragment, peptide, agonist,antagonist or aptamer.
 17. The conjugate of claim 13, wherein saidlinker comprises a combination of at least one amino acid andsubstituted or unsubstituted PEG.
 18. The conjugate of claim 13, whereinsaid dicarbonyl moiety is succinate.
 19. A pharmaceutical compositioncomprising a conjugate of claim 13 and a pharmaceutically acceptablecarrier.
 20. A method of treating a cancer in a subject in need thereof,the method comprising administering an effective amount of a conjugateof claim 13.